amnog-dev-bucket1000truekb-subset/2011-08-18_35a_Freistellung_2011-F-004.pdf2026-08-26T07:56:51.180Z"9ae2148e1ae59b121caa1e09de371481"57344STANDARD2206203922062039Normalkb-subset/2011-08-18_35a_Freistellung_2011-F-004_TrG.pdf2026-08-26T07:56:51.518Z"b9e17559b392c087b011322cfb9c3116"32625STANDARD2206203922062039Normalkb-subset/2011-08-18_35a_HMG-CoA-Reduktasehemmer_BAnz.pdf2026-08-26T07:56:51.515Z"148e2a1fbe95750380e9bf9c51bb3f8f"240375STANDARD2206203922062039Normalkb-subset/2011-08-18_35a_HMG-CoA-Reduktasehemmer_TrG.pdf2026-08-26T07:56:51.520Z"7884bf7c96a2599efbdc7c7faa3c5797"973185STANDARD2206203922062039Normalkb-subset/2011-12-15_AM-RL-XII_Ticagrelor_BAnz.pdf2026-08-26T07:56:51.511Z"454bd7505d4b6e38b48e586003473a92"261756STANDARD2206203922062039Normalkb-subset/2011-12-15_AM-RL-XII_Ticagrelor_TrG.pdf2026-08-26T07:56:51.407Z"ddb7d15f9fd0fd97a3de0c885dc7131d"119683STANDARD2206203922062039Normalkb-subset/2012-01-19_AM-RL-XII_Bromfenac_BAnz.pdf2026-08-26T07:56:51.454Z"e8236449d521b3432469502b398d686c"281254STANDARD2206203922062039Normalkb-subset/2012-01-19_AM-RL-XII_Bromfenac_TrG.pdf2026-08-26T07:56:51.452Z"85dbf173c486e3417a057b9532b983a0"111174STANDARD2206203922062039Normalkb-subset/2012-03-01_AM-RL-XII_Boceprevir_BAnz.pdf2026-08-26T07:56:51.513Z"78cf37435581df23e8504091ca162516"311636STANDARD2206203922062039Normalkb-subset/2012-03-01_AM-RL-XII_Boceprevir_TrG.pdf2026-08-26T07:56:51.510Z"72386675403fb4227e6a1d4d63d3090d"57629STANDARD2206203922062039Normalkb-subset/2012-03-15_AM-RL-XII_Azilsartan_20medoxomil_BAnz.pdf2026-08-26T07:56:51.511Z"400c87fc1356f701f21177bb17c2a33a"336109STANDARD2206203922062039Normalkb-subset/2012-03-15_AM-RL-XII_Azilsartan_medoxomil_TrG.pdf2026-08-26T07:56:51.524Z"078a920002aa730be0edb282ccaca866"2899304STANDARD2206203922062039Normalkb-subset/2012-03-15_AM-RL-XII_Pirfenidon_BAnz.pdf2026-08-26T07:56:51.272Z"bf3276a2772c9040809616ddd9f3042c"343080STANDARD2206203922062039Normalkb-subset/2012-03-15_AM-RL-XII_Pirfenidon_TrG.pdf2026-08-26T07:56:51.344Z"3642d3e2f6c6c9b1c7909a3f1824a755"58762STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Abirateron_BAnz.pdf2026-08-26T07:56:51.408Z"05ca2332974fed7c38cd9e6e146a8236"361558STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Abirateron_TrG.pdf2026-08-26T07:56:51.471Z"aa37ce6f684350bf21e5f7742aeb60ab"88233STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Cabazitaxel_BAnz.pdf2026-08-26T07:56:51.484Z"f73b67c8fb9ce4dd211adee426cbc634"371183STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Cabazitaxel_TrG.pdf2026-08-26T07:56:51.524Z"b8268c90ae03b3500921ae6d33ad1f8d"83376STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Fingolimod_BAnz.pdf2026-08-26T07:56:51.522Z"3cbb77c9ea5c1ce1ed0454022d390367"2171718STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Fingolimod_TrG.pdf2026-08-26T07:56:51.532Z"400732cb129ae9a1619c1b5d18d35b59"103035STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Linagliptin_BAnz.pdf2026-08-26T07:56:51.546Z"c2fb2d6c8026edf08316a95d23dc24c5"362447STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Linagliptin_TrG.pdf2026-08-26T07:56:51.585Z"87ac03e440d8e0620f685b41ce919128"90586STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Regadenoson_BAnz.pdf2026-08-26T07:56:51.582Z"90d87727e1ed4fb60827bf764aeb7890"340817STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Regadenoson_TrG.pdf2026-08-26T07:56:51.586Z"0658f0b8c8407cd845e053a5649f311f"73394STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Telaprevir_BAnz.pdf2026-08-26T07:56:51.589Z"a3d78d1fc56185819d9babfeb4f05fe3"392226STANDARD2206203922062039Normalkb-subset/2012-03-29_AM-RL-XII_Telaprevir_TrG.pdf2026-08-26T07:56:51.582Z"cdb6dd9c403cdb0dc0b5f1b622bd980e"70274STANDARD2206203922062039Normalkb-subset/2012-04-19_AM-RL-XII_Collagenase_BAnz.pdf2026-08-26T07:56:51.586Z"6b6543878404a0816995453d0607a526"291397STANDARD2206203922062039Normalkb-subset/2012-04-19_AM-RL-XII_Collagenase_TrG.pdf2026-08-26T07:56:51.585Z"279244c29354b6935d92f4fb1797a92f"86574STANDARD2206203922062039Normalkb-subset/2012-04-19_AM-RL-XII_Eribulin.pdf2026-08-26T07:56:51.593Z"4ec1c0d65443211039a7577128901f30"397262STANDARD2206203922062039Normalkb-subset/2012-04-19_AM-RL-XII_Eribulin_TrG.pdf2026-08-26T07:56:51.591Z"5d4e6669595ff10851cbdd9a1aae4848"99691STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-35a_Freistellung-Malariamittel.pdf2026-08-26T07:56:51.594Z"10cd18839b39fb99e68115154e734184"28195STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-35a_Freistellung-Malariamittel_TrG.pdf2026-08-26T07:56:51.593Z"5a48679d868d2aefce8ec171520a8df3"50072STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-35a_Freistellung_Beta-Lactam-Antibiotika.pdf2026-08-26T07:56:51.608Z"271911db14ba2fda7c609c222f38344e"28243STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-35a_Freistellung_Beta-Lactam-Antibiotika_TrG.pdf2026-08-26T07:56:51.644Z"9d2eec4b7b3cf9e94b6989b5cbfdcfcd"50123STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-XII_Aliskiren-Amlodipin_BAnz.pdf2026-08-26T07:56:51.647Z"057f8acff3b6410480d41c20a4ccffa2"280350STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-XII_Aliskiren-Amlodipin_TrG.pdf2026-08-26T07:56:51.653Z"c049684966706b6385c5c60b41827ab7"100673STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-XII_Retigabin_BAnz.pdf2026-08-26T07:56:51.654Z"66d9511045a62b87aba556b58ee8fe09"264458STANDARD2206203922062039Normalkb-subset/2012-05-03_AM-RL-XII_Retigabin_TrG.pdf2026-08-26T07:56:51.651Z"7e49becd06c44ffeb408a9935f75f777"86835STANDARD2206203922062039Normalkb-subset/2012-05-29_Wortprotokoll_Belatacept.pdf2026-08-26T07:56:51.656Z"bd11dac183fc4885ed5e3d81ea882e3e"163161STANDARD2206203922062039Normalkb-subset/2012-05-29_Wortprotokoll_Emtricitabin_Rilpivirin_Tenofovirdisoproxil.pdf2026-08-26T07:56:51.655Z"eea6ba312bae456af7832f2395b9128f"158627STANDARD2206203922062039Normalkb-subset/2012-05-29_Wortprotokoll_Rilpivirin.pdf2026-08-26T07:56:51.655Z"1b7c66f4394b63c01f275caed990f643"70511STANDARD2206203922062039Normalkb-subset/2012-06-07_AM-RL-XII_Apixaban_BAnz.pdf2026-08-26T07:56:51.654Z"1be2d16cfcb637c04b2ccaff86e5a7fc"349721STANDARD2206203922062039Normalkb-subset/2012-06-07_AM-RL-XII_Apixaban_TrG.pdf2026-08-26T07:56:51.662Z"0881a9f60248fe4cddcbf593871cf527"103285STANDARD2206203922062039Normalkb-subset/2012-06-07_AM-RL-XII_Tafamidis_BAnz.pdf2026-08-26T07:56:51.665Z"0e2d49238e702fa9c32cbfcce2883414"264763STANDARD2206203922062039Normalkb-subset/2012-06-07_AM-RL-XII_Tafamidis_TrG.pdf2026-08-26T07:56:51.675Z"6f268591655cd52bc2cbf67c1b09a3e8"61267STANDARD2206203922062039Normalkb-subset/2012-06-12_Wortprotokoll_Belimumab.pdf2026-08-26T07:56:51.709Z"99a1897d96accd5964b0813f18669ff9"414768STANDARD2206203922062039Normalkb-subset/2012-06-12_Wortprotokoll_Fampridin.pdf2026-08-26T07:56:51.714Z"d5f9bf6f35446a16a983b169d3f397a7"484175STANDARD2206203922062039Normalkb-subset/2012-06-12_Wortprotokoll_Ipilimumab.pdf2026-08-26T07:56:51.712Z"c889c6742d6524748ee34e257735a03f"152176STANDARD2206203922062039Normalkb-subset/2012-06-21_AM-RL-XII_Extrakte_20aus_20Cannabis_BAnz.pdf2026-08-26T07:56:51.714Z"63d8ef10c5eacac176c0e9eb09d0f64e"297220STANDARD2206203922062039Normalkb-subset/2012-06-21_AM-RL-XII_Extrakte_20aus_20Cannabis_TrG.pdf2026-08-26T07:56:51.720Z"7f14d3c36558d7e766bcada59e78ccd9"109589STANDARD2206203922062039Normalkb-subset/2012-07-05_AM-RL-XII_Belatacept_BAnz.pdf2026-08-26T07:56:51.723Z"30f0656b293908323f814d347dac746f"301783STANDARD2206203922062039Normalkb-subset/2012-07-05_AM-RL-XII_Belatacept_TrG.pdf2026-08-26T07:56:51.722Z"0ccfb55100133414cfe5e4e4aaae63c2"95607STANDARD2206203922062039Normalkb-subset/2012-07-05_AM-RL-XII_Emtricitabin-Rilpivirin-Tenofovir_BAnz.pdf2026-08-26T07:56:51.726Z"b388378587b55acb1db3d5290e622280"283374STANDARD2206203922062039Normalkb-subset/2012-07-05_AM-RL-XII_Emtricitabin-Rilpivirin-Tenofovir_TrG.pdf2026-08-26T07:56:51.728Z"d7ce042481a477f909082e408b92fb9e"117676STANDARD2206203922062039Normalkb-subset/2012-07-05_AM-RL-XII_Rilpivirin_BAnz.pdf2026-08-26T07:56:51.731Z"97435cf58b0519958a767f03e48ecc3c"277440STANDARD2206203922062039Normalkb-subset/2012-07-05_AM-RL-XII_Rilpivirin_TrG.pdf2026-08-26T07:56:51.730Z"4a877b23cb651019015e1db40d90757f"114209STANDARD2206203922062039Normalkb-subset/2012-07-24_Wortprotokoll_Vandetanib.pdf2026-08-26T07:56:51.733Z"bc5da15b953bc55fc02c4b60e3fb7a50"469938STANDARD2206203922062039Normalkb-subset/2012-07-24_Wortprotokoll_Vemurafenib.pdf2026-08-26T07:56:51.777Z"e067b182cbda0a522e692325f59dc30d"485253STANDARD2206203922062039Normalkb-subset/2012-08-02_AM-RL-XII_Belimumab_BAnz.pdf2026-08-26T07:56:51.779Z"f60530263b5ba7d0390287aa02f44d45"297576STANDARD2206203922062039Normalkb-subset/2012-08-02_AM-RL-XII_Belimumab_TrG.pdf2026-08-26T07:56:51.784Z"f2b9e9a4ee534aaf34ea93fb017c79c7"130072STANDARD2206203922062039Normalkb-subset/2012-08-02_AM-RL-XII_Fampridin_BAnz.pdf2026-08-26T07:56:51.785Z"b66ccb5526feecd604ead574aab6a0aa"267450STANDARD2206203922062039Normalkb-subset/2012-08-02_AM-RL-XII_Fampridin_TrG.pdf2026-08-26T07:56:51.782Z"ce1da3fc242f0d0d70399b166b47b404"92380STANDARD2206203922062039Normalkb-subset/2012-08-02_AM-RL-XII_Ipilimumab_BAnz.pdf2026-08-26T07:56:51.787Z"8cf76fb1dfd6d65ccf1b3e6f3536defe"289606STANDARD2206203922062039Normalkb-subset/2012-08-02_AM-RL-XII_Ipilimumab_TrG.pdf2026-08-26T07:56:51.788Z"562585076435e5aad00001fe1fe90fd4"116276STANDARD2206203922062039Normalkb-subset/2012-09-06_AM-RL-XII_Vandetanib_BAnz.pdf2026-08-26T07:56:51.791Z"9fa8f064c9b063275ff4b9bc7f610697"80713STANDARD2206203922062039Normalkb-subset/2012-09-06_AM-RL-XII_Vandetanib_TrG.pdf2026-08-26T07:56:51.793Z"6bba65c955ea2ce31fa543b4fa1252ed"93495STANDARD2206203922062039Normalkb-subset/2012-09-06_AM-RL-XII_Vemurafenib_BAnz.pdf2026-08-26T07:56:51.801Z"f6b65013749b472f73539e14aa7d9565"290478STANDARD2206203922062039Normalkb-subset/2012-09-06_AM-RL-XII_Vemurafenib_TrG.pdf2026-08-26T07:56:51.799Z"72ca91a78448113d245f2c79640ab080"105881STANDARD2206203922062039Normalkb-subset/2012-10-23_Wortprotokoll_end_Pasireotid.pdf2026-08-26T07:56:51.803Z"f0d4ea3eb6c0587fe25d54c791f1bc10"356156STANDARD2206203922062039Normalkb-subset/2012-11-06_Wortprotokoll_Tegafur-Gimeracil-Oteracil.pdf2026-08-26T07:56:51.859Z"92505df9308ae5dd2105ddb3a0a27ac7"180194STANDARD2206203922062039Normalkb-subset/2012-12-06_AM-RL-XII_Pasireotid_BAnz.pdf2026-08-26T07:56:51.859Z"96359877ed962f8f4827874d2a14d5e1"106553STANDARD2206203922062039Normalkb-subset/2012-12-06_AM-RL-XII_Pasireotid_TrG.pdf2026-08-26T07:56:51.864Z"f7c40a2a25f047f0c9e5a52555f6d649"92027STANDARD2206203922062039Normalkb-subset/2012-12-20_Tegafur-Gimeracil-Oteracil_BAnz.pdf2026-08-26T07:56:51.864Z"c111f51a5e98a548fc28d08734b25fa0"173710STANDARD2206203922062039Normalkb-subset/2012-12-20_Tegafur-Gimeracil-Oteracil_TrG.pdf2026-08-26T07:56:51.869Z"39e42b1928f38f350318f6268334b8df"195854STANDARD2206203922062039Normalkb-subset/2013-01-08_Wortprotokoll_20Ivacaftor.pdf2026-08-26T07:56:51.869Z"9e9123c602a676eebfc76a314ecee132"342142STANDARD2206203922062039Normalkb-subset/2013-01-08_Wortprotokoll_Linagliptin.pdf2026-08-26T07:56:51.872Z"b85f72238608b1ed381b7c933e91b65a"514638STANDARD2206203922062039Normalkb-subset/2013-01-29_Wortprotokoll_Perampanel.pdf2026-08-26T07:56:51.874Z"d89143a5114d851c599efcfae6bb7aa1"202764STANDARD2206203922062039Normalkb-subset/2013-01-29_Wortprotokoll_Ruxolitinib.pdf2026-08-26T07:56:51.874Z"24d64b241a35de49e05c0468a4ba2447"246432STANDARD2206203922062039Normalkb-subset/2013-02-07_AM-RL-XII_Ivacaftor_BAnz.pdf2026-08-26T07:56:51.874Z"76fc05e2625cebcf7bbf110edf88fa39"157076STANDARD2206203922062039Normalkb-subset/2013-02-07_AM-RL-XII_Ivacaftor_TrG.pdf2026-08-26T07:56:51.878Z"b9aa13298c9fbc4f7cc7d78e19529eef"88580STANDARD2206203922062039Normalkb-subset/2013-02-11_Axitinib_end_Wortprotokoll.pdf2026-08-26T07:56:51.878Z"a672cf978a749170eca128d8b5309aa3"113353STANDARD2206203922062039Normalkb-subset/2013-02-11_Wortprotokoll_end_Aclidiniumbromid.pdf2026-08-26T07:56:51.930Z"1c071d075f2aafe2bb8966b6ed0a97ea"153040STANDARD2206203922062039Normalkb-subset/2013-02-21_AM-RL-XII_Linagliptin_BAnz.pdf2026-08-26T07:56:51.930Z"947eb2895db9dfd2074e8d10ddd8978f"273671STANDARD2206203922062039Normalkb-subset/2013-02-21_AM-RL-XII_Linagliptin_TrG.pdf2026-08-26T07:56:51.928Z"9923206d2feb40ed89530dd5e42aac13"111132STANDARD2206203922062039Normalkb-subset/2013-03-07_AM-RL-XII_Perampanel_BAnz.pdf2026-08-26T07:56:51.933Z"5d7f2ed06a809592a9d0a098e7ba664b"93734STANDARD2206203922062039Normalkb-subset/2013-03-07_AM-RL-XII_Perampanel_TrG.pdf2026-08-26T07:56:51.934Z"03dcb0dbc02c0b5bdf3b968fda5a7caf"92501STANDARD2206203922062039Normalkb-subset/2013-03-07_AM-RL-XII_Ruxolitinib_BAnz.pdf2026-08-26T07:56:51.940Z"0ddb2d64406097a595910e30b993ae4a"162679STANDARD2206203922062039Normalkb-subset/2013-03-07_AM-RL-XII_Ruxolitinib_TrG.pdf2026-08-26T07:56:51.942Z"c597ca6f44c60ec8fb1ec2c98a156ea3"263348STANDARD2206203922062039Normalkb-subset/2013-03-12_Decitabin_Wortprotokoll.pdf2026-08-26T07:56:51.943Z"634ee2ce0bb42fffbabb5bf3c950ac4d"151352STANDARD2206203922062039Normalkb-subset/2013-03-21_AM-RL-XII_Aclidiniumbromid_BAnz.pdf2026-08-26T07:56:51.946Z"42779737bf71e179b3154c39e35addc6"126062STANDARD2206203922062039Normalkb-subset/2013-03-21_AM-RL-XII_Aclidiniumbromid_TrG.pdf2026-08-26T07:56:51.947Z"48a48f52f56bf8d0d1edcf7b9a6245bd"110575STANDARD2206203922062039Normalkb-subset/2013-03-21_AM-RL-XII_Axitinib.pdf2026-08-26T07:56:51.947Z"1eb88c815899b64891c6f272447c819c"111444STANDARD2206203922062039Normalkb-subset/2013-03-21_AM-RL-XII_Axitinib_TrG.pdf2026-08-26T07:56:51.947Z"f2b78bb8fc0ebcf5532503727d8852a2"129411STANDARD2206203922062039Normalkb-subset/2013-03-26_Wortprotokoll_Crizotinib.pdf2026-08-26T07:56:51.987Z"9741039a1bec0ec27820512556cc024b"152259STANDARD2206203922062039Normalkb-subset/2013-03-26_Wortprotokoll_Saxagliptin_Metformin.pdf2026-08-26T07:56:51.992Z"f799327782157d5a85421d5302be365b"189898STANDARD2206203922062039Normalkb-subset/2013-04-08_Wortprotokoll_Brentuximab_20Vedotin.pdf2026-08-26T07:56:52.000Z"4e3ba45ff86cd97820caff8641413d22"132274STANDARD2206203922062039Normalkb-subset/2013-04-08_Wortprotokoll_Linagliptin.pdf2026-08-26T07:56:52.002Z"2e87d3369b0235c6102e85202e61e4e3"208748STANDARD2206203922062039Normalkb-subset/2013-04-08_Wortprotokoll_Pixantron.pdf2026-08-26T07:56:52.008Z"306975cd7cbb44937947ed0b6213f342"126625STANDARD2206203922062039Normalkb-subset/2013-04-23_Wortprotokoll_Aflibercept.pdf2026-08-26T07:56:52.007Z"c53b72f1a1eb3d64d62cb010149391ee"154731STANDARD2206203922062039Normalkb-subset/2013-04-23_Wortprotokoll_Dapagliflozin_.pdf2026-08-26T07:56:52.012Z"e7412ae3bcc728e75ae04999fcabbf64"200163STANDARD2206203922062039Normalkb-subset/2013-05-02_AM-RL-XII_Crizotinib_BAnz.pdf2026-08-26T07:56:52.012Z"2e7e5b31ef6662575aaccc530c91a323"190719STANDARD2206203922062039Normalkb-subset/2013-05-02_AM-RL-XII_Crizotinib_TrG.pdf2026-08-26T07:56:52.014Z"a525f25699a0e2f1a2db6fba8f5d9eb7"106645STANDARD2206203922062039Normalkb-subset/2013-05-02_AM-RL-XII_Decitabin_BAnz.pdf2026-08-26T07:56:52.015Z"e25425a4878cb27da338819533894d57"127626STANDARD2206203922062039Normalkb-subset/2013-05-02_AM-RL-XII_Decitabin_TrG.pdf2026-08-26T07:56:52.021Z"caed60c1d4a778ef68fddfd436934e79"111875STANDARD2206203922062039Normalkb-subset/2013-05-02_AM-RL-XII_Saxagliptin_20Metformin_BAnz.pdf2026-08-26T07:56:52.015Z"da08f4d80319208b72277674daea778d"151647STANDARD2206203922062039Normalkb-subset/2013-05-02_AM-RL-XII_Saxagliptin_20Metformin_TrG.pdf2026-08-26T07:56:52.051Z"ad3e8a244c6af44d1ba9e8b91fa4b382"158913STANDARD2206203922062039Normalkb-subset/2013-05-07_Wortprotokoll_end_Apixaban.pdf2026-08-26T07:56:52.057Z"ec3528bd0f27ba9f6897ff3cef1003da"365476STANDARD2206203922062039Normalkb-subset/2013-05-16_AM-RL-XII_Brentuximab.pdf2026-08-26T07:56:52.073Z"5eb2f692b406e451ee4c0aafc9783ae6"165607STANDARD2206203922062039Normalkb-subset/2013-05-16_AM-RL-XII_Brentuximab_TrG.pdf2026-08-26T07:56:52.070Z"de96eaf3cb0b42ae12b6919d2c04f735"150883STANDARD2206203922062039Normalkb-subset/2013-05-16_AM-RL-XII_Linagliptin-neues-AWG_BAnz.pdf2026-08-26T07:56:52.070Z"6ef201e6f98be3e4ca68798fd1c1dbdd"224688STANDARD2206203922062039Normalkb-subset/2013-05-16_AM-RL-XII_Linagliptin-neues-AWG_TrG.pdf2026-08-26T07:56:52.076Z"2933be3a881d35499c3d9681521ed01a"91997STANDARD2206203922062039Normalkb-subset/2013-05-16_AM-RL-XII_Pixantron_BAnz.pdf2026-08-26T07:56:52.075Z"2f3f10265000766de4a6ddf15610b241"292005STANDARD2206203922062039Normalkb-subset/2013-05-16_AM-RL-XII_Pixantron_TrG.pdf2026-08-26T07:56:52.082Z"9ded16734e1c26ee80ded5f0e9b46641"133730STANDARD2206203922062039Normalkb-subset/2013-05-27_Wortprotokoll_Ingenolmebutat.pdf2026-08-26T07:56:52.086Z"a1b769198dad24a065403fa624252d91"349408STANDARD2206203922062039Normalkb-subset/2013-05-27_Wortprotokoll_end_Abirateronacetat.pdf2026-08-26T07:56:52.085Z"960cf6d3a8f0b09020033dd80aaad79a"121026STANDARD2206203922062039Normalkb-subset/2013-05-27_Wortprotokoll_end_Fidaxomicin.pdf2026-08-26T07:56:52.096Z"d91b30b1991df230d9c67c7641f69df0"191240STANDARD2206203922062039Normalkb-subset/2013-06-06_AM-RL-XII_Aflibercept_BAnz.pdf2026-08-26T07:56:52.101Z"12c890050a44d22affe6636a65f8700a"94428STANDARD2206203922062039Normalkb-subset/2013-06-06_AM-RL-XII_Aflibercept_TrG.pdf2026-08-26T07:56:52.123Z"a91019ee83d4662463ac7a7b03297bdf"84718STANDARD2206203922062039Normalkb-subset/2013-06-06_AM-RL-XII_Dapagliflozin_BAnz.pdf2026-08-26T07:56:52.133Z"eadabf419253c216049410f43fdab8b9"164873STANDARD2206203922062039Normalkb-subset/2013-06-06_AM-RL-XII_Dapagliflozin_TrG.pdf2026-08-26T07:56:52.133Z"df5d12f9594546943630b2e9d7a812fa"174293STANDARD2206203922062039Normalkb-subset/2013-06-20_AM-RL-XII_Aclidiniumbromid_Aenderungsbeschluss_BAnz.pdf2026-08-26T07:56:52.137Z"ba2b80e606f6a4c1b31fdfe4b50ae077"90730STANDARD2206203922062039Normalkb-subset/2013-06-20_AM-RL-XII_Apixaban-neues-AWG_BAnz.pdf2026-08-26T07:56:52.138Z"f0562220adcc96f0fe584f6f613c2ac1"129900STANDARD2206203922062039Normalkb-subset/2013-06-20_AM-RL-XII_Apixaban-neues-AWG_TrG.pdf2026-08-26T07:56:52.146Z"ad93c8198536f0d9289fab94798bb294"142708STANDARD2206203922062039Normalkb-subset/2013-07-04_AM-RL-XII_Abirateronacetat-neuesAWG_BAnz.pdf2026-08-26T07:56:52.143Z"c36fab024b3fde84cb8fbc8ec83be306"122645STANDARD2206203922062039Normalkb-subset/2013-07-04_AM-RL-XII_Abirateronacetat-neuesAWG_TrG.pdf2026-08-26T07:56:52.146Z"1ceb0f54578f903bb738aab914993a31"294087STANDARD2206203922062039Normalkb-subset/2013-07-04_AM-RL-XII_Fidaxomicin_BAnz.pdf2026-08-26T07:56:52.155Z"45fc4210cb855b66ce4c2d2adaf94696"143802STANDARD2206203922062039Normalkb-subset/2013-07-04_AM-RL-XII_Fidaxomicin_TrG.pdf2026-08-26T07:56:52.157Z"6aa41f509c8b8b5d42651cac1e550277"118818STANDARD2206203922062039Normalkb-subset/2013-07-04_AM-RL-XII_Ingenolmebutat_BAnz.pdf2026-08-26T07:56:52.160Z"51e9f4fcbd836bc9ba80ce709aec65c0"143641STANDARD2206203922062039Normalkb-subset/2013-07-04_AM-RL-XII_Ingenolmebutat_TrG.pdf2026-08-26T07:56:52.171Z"47596348b8d59c1ba6a56d5152559c98"96132STANDARD2206203922062039Normalkb-subset/2013-07-09_Wortprotokoll_end_Aflibercept.pdf2026-08-26T07:56:52.189Z"bdab2ad2aff17e8407611f01637b3a31"160759STANDARD2206203922062039Normalkb-subset/2013-07-23_Wortprotokoll_Lixisenatid.pdf2026-08-26T07:56:52.194Z"692bb2d845830ce088adac097bd4a39d"106470STANDARD2206203922062039Normalkb-subset/2013-07-23_Wortprotokoll_Vandetanib.pdf2026-08-26T07:56:52.200Z"de323c37317285613355c9e9c0c46bd1"125045STANDARD2206203922062039Normalkb-subset/2013-08-05_Wortprotokoll_Gliptine.pdf2026-08-26T07:56:52.201Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalkb-subset/2013-08-05_Wortprotokoll_Gliptine_Dm9XgbO.pdf2026-08-26T07:56:52.203Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalkb-subset/2013-08-05_Wortprotokoll_Gliptine_Sxya9D7.pdf2026-08-26T07:56:52.216Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalkb-subset/2013-08-05_Wortprotokoll_Gliptine_dP0A5Kh.pdf2026-08-26T07:56:52.214Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalkb-subset/2013-08-05_Wortprotokoll_Gliptine_rHn9hMI.pdf2026-08-26T07:56:52.219Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalkb-subset/2013-08-05_Wortprotokoll_Gliptine_uLzqjG6.pdf2026-08-26T07:56:52.219Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalkb-subset/2013-08-05_Wortprotokoll_Pertuzumab.pdf2026-08-26T07:56:52.222Z"900565a251c8af4b18e7aa837e91903c"392531STANDARD2206203922062039Normalkb-subset/2013-08-09_Wortprotokoll_Colestilan.pdf2026-08-26T07:56:52.233Z"45f903af2540f4bc42ef41983c299f50"126898STANDARD2206203922062039Normalkb-subset/2013-08-15_AM-RL-35a_Einstellung-Retigabin.pdf2026-08-26T07:56:52.234Z"40bd8b2e502454679313eb0fbfb346f4"29402STANDARD2206203922062039Normalkb-subset/2013-08-15_AM-RL-35a_Einstellung-Retigabin_TrG.pdf2026-08-26T07:56:52.254Z"89b9aeac8c32c460967639c33cdd5edf"59753STANDARD2206203922062039Normalkb-subset/2013-08-15_AM-RL-XII_Aflibercept_BAnz.pdf2026-08-26T07:56:52.262Z"358187eb23ee03713e623b0fc4d92bca"165529STANDARD2206203922062039Normalkb-subset/2013-08-15_AM-RL-XII_Aflibercept_TrG.pdf2026-08-26T07:56:52.267Z"c98dd722e37106fdca379f93c5386d1d"145413STANDARD2206203922062039Normalkb-subset/2013-09-05_AM-RL-XII_Lixisenatid_BAnz.pdf2026-08-26T07:56:52.269Z"6f9250e8ce15f9363201dbb8b9530eda"181802STANDARD2206203922062039Normalkb-subset/2013-09-05_AM-RL-XII_Lixisenatid_TrG.pdf2026-08-26T07:56:52.281Z"d898521d248c49b3fe6b8264936d34a1"177475STANDARD2206203922062039Normalkb-subset/2013-09-05_AM-RL-XII_Vandetanib_BAnz.pdf2026-08-26T07:56:52.283Z"9c32b1d7de465c0b06b5be6310eae7bc"133430STANDARD2206203922062039Normalkb-subset/2013-09-05_AM-RL-XII_Vandetanib_D-059_EN.pdf2026-08-26T07:56:52.287Z"1863fcb04b25ecc3f3cf8e03e11583aa"1264241STANDARD2206203922062039Normalkb-subset/2013-09-05_AM-RL-XII_Vandetanib_D-059_TrG_EN.pdf2026-08-26T07:56:52.291Z"5a4d1a7892f8965090737eca03987684"743830STANDARD2206203922062039Normalkb-subset/2013-09-05_AM-RL-XII_Vandetanib_TrG.pdf2026-08-26T07:56:52.286Z"7486d496c6382b31df6c34546f2bc07d"137126STANDARD2206203922062039Normalkb-subset/2013-09-09_Bosutinib_Wortprotokoll.pdf2026-08-26T07:56:52.293Z"d6ea5d28786640defe7fb3988c350f60"87346STANDARD2206203922062039Normalkb-subset/2013-09-09_Wortprotokoll_End_Ocriplasmin.pdf2026-08-26T07:56:52.304Z"801a4491aeaf9467c5171e7c8417c689"201446STANDARD2206203922062039Normalkb-subset/2013-09-09_Wortprotokoll_end_Linaclotid.pdf2026-08-26T07:56:52.313Z"64d14a426a8389141e2ba1e6e6de33ed"234255STANDARD2206203922062039Normalkb-subset/2013-09-19_35a_Freistellung-Spinalanaesthesie.pdf2026-08-26T07:56:52.316Z"79eeef956ba09ced44398c730e53b879"28318STANDARD2206203922062039Normalkb-subset/2013-09-19_35a_Freistellung-Spinalanaesthesie_TrG.pdf2026-08-26T07:56:52.329Z"f1636da7a3ae2b67b0a03a37b4dfc0bd"52106STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Colestilan_BAnz_WZ.pdf2026-08-26T07:56:52.327Z"b404012dc4c17fc4a6053b2ad1d930fc"127749STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Colestilan_TrG_WZ.pdf2026-08-26T07:56:52.338Z"be165c07ae60c92dedb7f5a273aa01ff"596864STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Pertuzumab_BAnz.pdf2026-08-26T07:56:52.351Z"e2bc63dfc4ab484ab6fe68ea228a046e"152298STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Pertuzumab_TrG.pdf2026-08-26T07:56:52.349Z"a86518d799ac1136afeb989002ce5e3b"145004STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Saxagliptin-Metformin_nAWG_BAnz.pdf2026-08-26T07:56:52.355Z"84b0c2fc263dbbd574cd07469d489a11"92603STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Saxagliptin-Metformin_nAWG_TrG.pdf2026-08-26T07:56:52.354Z"218e14e8ebc641bb30a09693261c48da"128933STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Saxagliptin_BAnz.pdf2026-08-26T07:56:52.360Z"456a2386ca06fdf317f0998442e84ba9"218814STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Saxagliptin_TrG.pdf2026-08-26T07:56:52.358Z"38ff13b44f5fa6855ba8703145ea8c93"195865STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Sitagliptin-Metformin_BAnz.pdf2026-08-26T07:56:52.380Z"b04b5362937ca53f6e1bda12a39c35a5"196541STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Sitagliptin-Metformin_TrG.pdf2026-08-26T07:56:52.383Z"79b8ca4b71e109b29e6068ba4971bea5"190645STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Sitagliptin_BAnz.pdf2026-08-26T07:56:52.386Z"0fd1970ab5cec7b56235b9b1597c5542"248061STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Sitagliptin_TrG.pdf2026-08-26T07:56:52.396Z"680c6ff998a4ea83eba269b26f698ee5"230893STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Vildagliptin-Metformin_BAnz.pdf2026-08-26T07:56:52.399Z"876b5548aaca1044e2843be3d5d4bbcb"343662STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Vildagliptin-Metformin_TrG.pdf2026-08-26T07:56:52.402Z"5d0b160a5ffd94a17d03f84ac8447af2"166577STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Vildagliptin_BAnz.pdf2026-08-26T07:56:52.420Z"07e65b110b19325d226d39f5f06a04d7"214592STANDARD2206203922062039Normalkb-subset/2013-10-01_AM-RL-XII_Vildagliptin_TrG.pdf2026-08-26T07:56:52.420Z"0bd61cd1d191e9b9c7feada2b1605e31"204712STANDARD2206203922062039Normalkb-subset/2013-10-08_Wortprotokoll_end_Lisdexamfetamindimesilat.pdf2026-08-26T07:56:52.422Z"c3919c7ba33c20082788c716fb3bd017"125074STANDARD2206203922062039Normalkb-subset/2013-10-17_AM-RL-XII_Bosutinib_BAnz.pdf2026-08-26T07:56:52.426Z"11aef40c1cc951a566b2062554820736"188703STANDARD2206203922062039Normalkb-subset/2013-10-17_AM-RL-XII_Bosutinib_TrG.pdf2026-08-26T07:56:52.429Z"46afbfb13c53474a8b034a8e0225f6f2"179665STANDARD2206203922062039Normalkb-subset/2013-10-17_AM-RL-XII_Linaclotid_BAnz.pdf2026-08-26T07:56:52.433Z"51b853d374819d0ac9fdb406e0355333"97151STANDARD2206203922062039Normalkb-subset/2013-10-17_AM-RL-XII_Linaclotid_TrG.pdf2026-08-26T07:56:52.455Z"acf458055f1475691e1eae071520817b"213925STANDARD2206203922062039Normalkb-subset/2013-10-17_AM-RL-XII_Ocriplasmin_BAnz.pdf2026-08-26T07:56:52.455Z"de1b4f534e57197aa54ba358ddf6e367"111471STANDARD2206203922062039Normalkb-subset/2013-10-17_AM-RL-XII_Ocriplasmin_TrG.pdf2026-08-26T07:56:52.457Z"6cbe46c084a76bdd46526f78f7cfdad0"144854STANDARD2206203922062039Normalkb-subset/2013-10-22_Wortprotokoll_end_Elvitegravir-Cobicistat-Emtricitabin-Tenof.pdf2026-08-26T07:56:52.462Z"6136ff7fd836705844706a96b15a4497"162060STANDARD2206203922062039Normalkb-subset/2013-11-05_Wortprotokoll_Nepafenac.pdf2026-08-26T07:56:52.461Z"278506a5e75bdf263a637d215dd49c48"72846STANDARD2206203922062039Normalkb-subset/2013-11-14_AM-RL-XII_Lisdexamfetamin_BAnz.pdf2026-08-26T07:56:52.483Z"846952c8ab1ccb3395a98ea704af3acd"95665STANDARD2206203922062039Normalkb-subset/2013-11-14_AM-RL-XII_Lisdexamfetamin_TrG.pdf2026-08-26T07:56:52.492Z"7ad3b81d0d8974f18a595e18b6d0dd6a"96971STANDARD2206203922062039Normalkb-subset/2013-12-05_35a_Freistellung_Defibrotid.pdf2026-08-26T07:56:52.493Z"7a00f5f86120bbcb832e120cf14a6740"28222STANDARD2206203922062039Normalkb-subset/2013-12-05_35a_Freistellung_Defibrotid_TrG.pdf2026-08-26T07:56:52.492Z"70379a01631086af9f693ea1782e5c34"51287STANDARD2206203922062039Normalkb-subset/2013-12-05_AM-RL-XII_Elvi_Cobi_Emtr_Teno_BAnz.pdf2026-08-26T07:56:52.496Z"0e6a28c318ad360ea48aaf2b56939f15"133858STANDARD2206203922062039Normalkb-subset/2013-12-05_AM-RL-XII_Elvi_Cobi_Emtr_Teno_TrG.pdf2026-08-26T07:56:52.494Z"57a7b679f32c604205a514c6170d8f99"162170STANDARD2206203922062039Normalkb-subset/2013-12-10_Wortprotokoll_Ponatinib.pdf2026-08-26T07:56:52.499Z"50881da8c0d574fad8253cf3acc6bdfa"195279STANDARD2206203922062039Normalkb-subset/2013-12-19_AM-RL-XII_Nepafenac_BAnz.pdf2026-08-26T07:56:52.520Z"3ea26deeb304a637822414d1f3fce85c"97992STANDARD2206203922062039Normalkb-subset/2013-12-19_AM-RL-XII_Nepafenac_TrG.pdf2026-08-26T07:56:52.524Z"2662385876bdabc6a8eefdffda36922f"86408STANDARD2206203922062039Normalkb-subset/2014-01-12_Wortprotokoll_end_Apixaban.pdf2026-08-26T07:56:52.525Z"ab958de2e4dae6a9e34ada7fb94ef527"150148STANDARD2206203922062039Normalkb-subset/2014-01-12_Wortprotokoll_end_Teduglutid.pdf2026-08-26T07:56:52.528Z"c91db67f76be94fa49effab95df25224"132963STANDARD2206203922062039Normalkb-subset/2014-01-13_Wortprotokoll_end_Enzalutamid.pdf2026-08-26T07:56:52.547Z"66d6cfc8b8196adf3339bfa62b195e51"108182STANDARD2206203922062039Normalkb-subset/2014-01-13_Wortprotokoll_end_Pomalidomid.pdf2026-08-26T07:56:52.547Z"8f6c42461d60bc49f5f1d506d9ea8a79"142078STANDARD2206203922062039Normalkb-subset/2014-01-13_Wortprotokoll_end_Vismodegib.pdf2026-08-26T07:56:52.553Z"756f7fb1bbf9e4ce840a8342600d4f55"167334STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Dapagliflozin_2012-12-15-D-045_TK_BAnz.pdf2026-08-26T07:56:52.561Z"87236ae17744dca0cb2bce20b0a4056c"105543STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Linaclotid_TK_BAnz.pdf2026-08-26T07:56:52.560Z"4e1b5129a511ba0c7ae18c2622fb4fa0"133984STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Linagliptin_5b_2012-09-01-D-035_TK_BAnz.pdf2026-08-26T07:56:52.560Z"f9b22a774ebcf83fd358c1e4e761f7cd"159150STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Linagliptin_nAWG_2012-12-01-D-047_TK_BAnz.pdf2026-08-26T07:56:52.568Z"11086b46e72bad0c3fa937f4d4ac8b04"151610STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Lixisenatid_2013-03-15-D-061_TK_BAnz.pdf2026-08-26T07:56:52.570Z"e16013b2240dd7d8914036cc58276ce9"187952STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Ponatinib_BAnz.pdf2026-08-26T07:56:52.590Z"d8524fa862bcb5521f398385d9196da6"128729STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Ponatinib_D-071_EN.pdf2026-08-26T07:56:52.594Z"f5a20ee6dcfb57381ba73cf9c006b2a1"1257510STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Ponatinib_D-071_TrG_EN.pdf2026-08-26T07:56:52.599Z"c160fd6b15e4d2bc526f889027c48333"729098STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Ponatinib_TrG.pdf2026-08-26T07:56:52.594Z"4056e9c7fdbedd43a7418b1b96bc55f4"141030STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Saxagliptin-Metformin-nAWG_2013-04-01-D-063_TK_BAnz.pdf2026-08-26T07:56:52.624Z"6f6ce18c3e8961608428d6a3675baafd"159726STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Saxagliptin-Metformin_Therapiek_BAnz.pdf2026-08-26T07:56:52.625Z"0ed0c378c3d274bd5bb32e145a420069"104250STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Saxagliptin_2013-04-01-D-050_TK_BAnz.pdf2026-08-26T07:56:52.628Z"517e8efc8cb62e7b8314d305741f1cd1"122193STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Sitagliptin_2013-04-01-D-054_TK_BAnz.pdf2026-08-26T07:56:52.628Z"ddea7189f8e2de4405efcc37fc1ac2b4"121528STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Sitagliptin_M_2013-04-01-D-055_TK_BAnz.pdf2026-08-26T07:56:52.634Z"a0b8894115dc305c65651062ccdd371b"112258STANDARD2206203922062039Normalkb-subset/2014-01-23_AM-RL-XII_Vildagliptin-Metformin_2013-04-01-D-048_TK_BAnz.pdf2026-08-26T07:56:52.633Z"2ca6fc7cf9a7bdfd7edbd579f49fb0bc"160456STANDARD2206203922062039Normalkb-subset/2014-01-28_Wortprotokoll_end_Vemurafenib.pdf2026-08-26T07:56:52.638Z"607c12586877a6d0fea2e273cd58d6d9"297894STANDARD2206203922062039Normalkb-subset/2014-02-06_AM-RL-XII_Vismodegib_2013-08-15-D-069_BAnz.pdf2026-08-26T07:56:52.636Z"3e8e50a4f28311898928d7c6048514b3"160095STANDARD2206203922062039Normalkb-subset/2014-02-06_AM-RL-XII_Vismodegib_2013-08-15-D-069_TrG.pdf2026-08-26T07:56:52.659Z"9433abbc5b4299cee1f8f6fd2033b4ce"144785STANDARD2206203922062039Normalkb-subset/2014-02-10-Wortprotokoll_end_Aflibercept.pdf2026-08-26T07:56:52.671Z"72f9d01e5dc16913ff872e066169f0b6"161624STANDARD2206203922062039Normalkb-subset/2014-02-10_Wortprotokoll_end_Regorafenib.pdf2026-08-26T07:56:52.668Z"6d15721392c6413c182f90667d4cfeab"206118STANDARD2206203922062039Normalkb-subset/2014-02-10_Wortprotokoll_end_Teriflunomid.pdf2026-08-26T07:56:52.671Z"6e1f7ae551fcc1a382f85930a6689caa"288311STANDARD2206203922062039Normalkb-subset/2014-02-10_Wortprotokoll_end_korr_Dabrafenib.pdf2026-08-26T07:56:52.699Z"ddc99416ec005e9deda5aeef88908961"227969STANDARD2206203922062039Normalkb-subset/2014-02-20_AM-RL-XII_Colestilan_Aenderungsbeschluss_BAnz.pdf2026-08-26T07:56:52.695Z"569e692728f3b8b0d332f1fa17de7133"138567STANDARD2206203922062039Normalkb-subset/2014-02-20_AM-RL-XII_Enzalutamid_2013-09-01-D-073_BAnz.pdf2026-08-26T07:56:52.698Z"3b5753cd482bd7ad73cb67341a6b10a1"99331STANDARD2206203922062039Normalkb-subset/2014-02-20_AM-RL-XII_Enzalutamid_2013-09-01-D-073_TrG.pdf2026-08-26T07:56:52.695Z"472a492846f1ff450e9651ce033d2f7c"129174STANDARD2206203922062039Normalkb-subset/2014-02-20_AM-RL-XII_Pomalidomid_2013-09-01-D-075_BAnz.pdf2026-08-26T07:56:52.696Z"a0ad245f91ad0421ae7b2ae77f44d224"141478STANDARD2206203922062039Normalkb-subset/2014-02-20_AM-RL-XII_Pomalidomid_2013-09-01-D-075_TrG.pdf2026-08-26T07:56:52.696Z"ea78bd0af5f17cb5c982d52ff8ccc7c1"221130STANDARD2206203922062039Normalkb-subset/2014-03-06_AM-RL-XII_Vemurafenib_2013-09-15-D-074_BAnz.pdf2026-08-26T07:56:52.702Z"ad15ec80fbf3205ad49faeae16b3fad4"178246STANDARD2206203922062039Normalkb-subset/2014-03-06_AM-RL-XII_Vemurafenib_2013-09-15-D-074_TrG.pdf2026-08-26T07:56:52.715Z"a860a7cf452b729d48601b85daf51aed"114977STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_BAnz.pdf2026-08-26T07:56:52.725Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_BRuNYH1.pdf2026-08-26T07:56:52.738Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_NbKqUHc.pdf2026-08-26T07:56:52.736Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_PHKzhjx.pdf2026-08-26T07:56:52.742Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_Vwm9C0x.pdf2026-08-26T07:56:52.759Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_TrG.pdf2026-08-26T07:56:52.764Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_TrG_NT2QP8L.pdf2026-08-26T07:56:52.766Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_TrG_OZaVoIQ.pdf2026-08-26T07:56:52.771Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_TrG_dxQF0ux.pdf2026-08-26T07:56:52.772Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalkb-subset/2014-03-17_35a_EinstellungBestandsmarkt_TrG_gszMm7f.pdf2026-08-26T07:56:52.774Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII-IX_KombiGluco-lwBeta2_Sympathomimetika_G1S3_BAnz.pdf2026-08-26T07:56:52.778Z"c34e74e37ac72fe0ebf424133f50e9ee"63613STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII-IX_KombiGluco-lwBeta2_Sympathomimetika_G1S3_TrG.pdf2026-08-26T07:56:52.791Z"8fc32f21a9c6e981f94d229c621fdedb"4782126STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII_Aflibercept-nAWG_2013-10-01-D-080_BAnz.pdf2026-08-26T07:56:52.795Z"177a06eb457d5fecd2b86caadbd433bd"100839STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII_Aflibercept-nAWG_2013-10-01-D-080_TrG.pdf2026-08-26T07:56:52.813Z"2e50d2cd22b441fae30344d989176697"153092STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII_Regorafenib_2013-10-01-D-077_BAnz.pdf2026-08-26T07:56:52.810Z"d417b81572c6f34ea8a3fee50bb8834e"122213STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII_Regorafenib_2013-10-01-D-077_TrG.pdf2026-08-26T07:56:52.814Z"d8b06c3ce5f196207236161ac264c908"230827STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII_Teriflunomid_2013-10-01-D-078_BAnz.pdf2026-08-26T07:56:52.823Z"f43c4ddbe268efe9a1daaee61a85c988"124874STANDARD2206203922062039Normalkb-subset/2014-03-20_AM-RL-XII_Teriflunomid_2013-10-01-D-078_TrG.pdf2026-08-26T07:56:52.832Z"b97d801cba4a36cefd349953dc2fa296"169420STANDARD2206203922062039Normalkb-subset/2014-03-25-Wortprotokoll_end_Indacaterol_Glycopyrronium.pdf2026-08-26T07:56:52.841Z"8be60b197e435e5c9863d4a3d4421eb4"188850STANDARD2206203922062039Normalkb-subset/2014-03-25_Wortprotokoll_end_Afatinib.pdf2026-08-26T07:56:52.832Z"19edf4f6dcb6dea6060f0b221fa65af4"275243STANDARD2206203922062039Normalkb-subset/2014-04-03_AM-RL-XII_Dabrafenib_2013-10-01-D-076_BAnz.pdf2026-08-26T07:56:52.837Z"a4e32e585849ed7e473c873b02398ae5"118734STANDARD2206203922062039Normalkb-subset/2014-04-03_AM-RL-XII_Dabrafenib_2013-10-01-D-076_TrG.pdf2026-08-26T07:56:52.837Z"bcf54b8200188a7a0683b7e27595be3b"284953STANDARD2206203922062039Normalkb-subset/2014-04-17_35a_Freistellung-2014-F-00.pdf2026-08-26T07:56:52.854Z"f932fc3387fa241f04b46c9d4a0e7c93"28406STANDARD2206203922062039Normalkb-subset/2014-04-17_35a_Freistellung-2014-F-00_TrG.pdf2026-08-26T07:56:52.858Z"2c8576063821610b22ad00e0510517cc"52092STANDARD2206203922062039Normalkb-subset/2014-04-17_35a_Freistellung-2014-F-00_TrG_XjN5pRp.pdf2026-08-26T07:56:52.869Z"2c8576063821610b22ad00e0510517cc"52092STANDARD2206203922062039Normalkb-subset/2014-04-17_35a_Freistellung-2014-F-00_jv13vS7.pdf2026-08-26T07:56:52.876Z"f932fc3387fa241f04b46c9d4a0e7c93"28406STANDARD2206203922062039Normalkb-subset/2014-04-29_Wortprotokoll_end_Ipilimumab_nAWG.pdf2026-08-26T07:56:52.877Z"f2efceb144a9c45ec1e6b590c72a5bd5"133269STANDARD2206203922062039Normalkb-subset/2014-04-29_Wortprotokoll_end_Lomitapid.pdf2026-08-26T07:56:52.888Z"e96e9e18de531400f740f0ad8f339ceb"122447STANDARD2206203922062039Normalkb-subset/2014-05-08_AM-RL-XII_Afatinib_2013-11-15-D-082_BAnz.pdf2026-08-26T07:56:52.890Z"1984925f71c5d40afac486923651df74"734737STANDARD2206203922062039Normalkb-subset/2014-05-08_AM-RL-XII_Afatinib_2013-11-15-D-082_TrG.pdf2026-08-26T07:56:52.903Z"8a97cb1b99a04c6733d79b0ea3ebca2b"168005STANDARD2206203922062039Normalkb-subset/2014-05-08_AM-RL-XII_Indacaterol-Glycopyrronium_2013-11-15-D-081_BAnz.pdf2026-08-26T07:56:52.904Z"7b5d9d825cba43523e10c734db6ce9b1"163407STANDARD2206203922062039Normalkb-subset/2014-05-08_AM-RL-XII_Indacaterol-Glycopyrronium_2013-11-15-D-081_TrG.pdf2026-08-26T07:56:52.906Z"85be18395203b6a6e4d10f42203d5568"145095STANDARD2206203922062039Normalkb-subset/2014-05-12_Wortprotokoll_Radium-223.pdf2026-08-26T07:56:52.911Z"dc86e7dc612f2a2cb42bc6918f10d6aa"239420STANDARD2206203922062039Normalkb-subset/2014-05-12_Wortprotokoll_Trastuzumab-Emtansin.pdf2026-08-26T07:56:52.916Z"e1073152779229c73e943d4072d8905d"372515STANDARD2206203922062039Normalkb-subset/2014-05-12_Wortprotokoll_end_Rilpivirin-Kombi.pdf2026-08-26T07:56:52.918Z"ce1237d65343913261dd8a877b46875c"108603STANDARD2206203922062039Normalkb-subset/2014-05-27_Wortprotokoll_end_Retigabin.pdf2026-08-26T07:56:52.923Z"77411e5c9bb781c525a907741e7049e8"134160STANDARD2206203922062039Normalkb-subset/2014-05-27_Wortprotokoll_end_Turoctocog-alfa.pdf2026-08-26T07:56:52.931Z"672dc2ba9a8767d97de42b9720832fb6"183594STANDARD2206203922062039Normalkb-subset/2014-06-05_AM-RL-XII_Ipilimumab_nAwg_2013-12-15-D-090_BAnz.pdf2026-08-26T07:56:52.940Z"9e0351fe8584eb1314d2743963d6a135"810036STANDARD2206203922062039Normalkb-subset/2014-06-05_AM-RL-XII_Ipilimumab_nAwg_2013-12-15-D-090_TrG.pdf2026-08-26T07:56:52.940Z"e3860537dafacecc7eac822d7e7f3675"307072STANDARD2206203922062039Normalkb-subset/2014-06-05_AM-RL-XII_Lomitapid_2013-12-15-D-093_BAnz.pdf2026-08-26T07:56:52.956Z"6849e49e46b35de48f8d472b9f8acd4f"143925STANDARD2206203922062039Normalkb-subset/2014-06-05_AM-RL-XII_Lomitapid_2013-12-15-D-093_TrG.pdf2026-08-26T07:56:52.957Z"c7b52cd51d5b79ee2bf40c24bf4cedb3"104907STANDARD2206203922062039Normalkb-subset/2014-06-10_Wortprotokoll_end_Macitentan.pdf2026-08-26T07:56:52.962Z"65868e8daa8dbdb36ef849e599ee6e9e"147778STANDARD2206203922062039Normalkb-subset/2014-06-10_Wortprotokoll_end_Sofosbuvir.pdf2026-08-26T07:56:52.963Z"f150b809ec1b44ff15fd8e2ba4173cb9"328296STANDARD2206203922062039Normalkb-subset/2014-06-19_AM-RL-XII_Radium-223_2014-01-01-D-094_BAnz.pdf2026-08-26T07:56:52.975Z"44223f9707d6203527cb41868fc8f2bc"587977STANDARD2206203922062039Normalkb-subset/2014-06-19_AM-RL-XII_Radium-223_2014-01-01-D-094_TrG.pdf2026-08-26T07:56:52.976Z"d1d2014966ebec0dbb2f235cb71f2001"294193STANDARD2206203922062039Normalkb-subset/2014-06-19_AM-RL-XII_Rilpivirin-Kombi_2014-01-01-D-089_BAnz.pdf2026-08-26T07:56:52.979Z"f1ebff1a2085e892bb33ef4fd161962f"550319STANDARD2206203922062039Normalkb-subset/2014-06-19_AM-RL-XII_Rilpivirin-Kombi_2014-01-01-D-089_TrG.pdf2026-08-26T07:56:52.981Z"a6e2f5c1365408fd0697a0ecf749ec3a"123304STANDARD2206203922062039Normalkb-subset/2014-06-19_AM-RL-XII_Trastuzumab-Emtansin_2014-01-01-D-084_BAnz.pdf2026-08-26T07:56:52.986Z"8d174fedc873ff7cfbc8b14fd83c64b1"658581STANDARD2206203922062039Normalkb-subset/2014-06-19_AM-RL-XII_Trastuzumab-Emtansin_2014-01-01-D-084_TrG.pdf2026-08-26T07:56:52.999Z"6f41354c39f70a19e1a90b20350660b7"153922STANDARD2206203922062039Normalkb-subset/2014-06-24_Wortprotokoll_end_Dapagliflozin-Metformin.pdf2026-08-26T07:56:53.009Z"e7cda159b3ae1d3112a45df74a116834"322567STANDARD2206203922062039Normalkb-subset/2014-06-24_Wortprotokoll_end_Dolutegravir.pdf2026-08-26T07:56:53.009Z"7088b189eb4ebf0944cffd59bee62d8b"308501STANDARD2206203922062039Normalkb-subset/2014-07-03_AM-RL-XII_Retigabin_2014-01-15-D-098_BAnz.pdf2026-08-26T07:56:53.025Z"72923410cbc75ef69f9e31c1cad96bbe"545115STANDARD2206203922062039Normalkb-subset/2014-07-03_AM-RL-XII_Retigabin_2014-01-15-D-098_TrG.pdf2026-08-26T07:56:53.022Z"f94aed5b4607f6a1fb54f353de4651e9"99215STANDARD2206203922062039Normalkb-subset/2014-07-03_AM-RL-XII_Turoctocog_20alfa_2014-01-15-D-092_BAnz.pdf2026-08-26T07:56:53.028Z"8eac9266a23e826db1a9caf3b141b3c7"133565STANDARD2206203922062039Normalkb-subset/2014-07-03_AM-RL-XII_Turoctocog_20alfa_2014-01-15-D-092_TrG.pdf2026-08-26T07:56:53.031Z"acfcbb12b294cb486b9a6e7a68b7ee3a"110456STANDARD2206203922062039Normalkb-subset/2014-07-17_AM-RL-IX-XII_Beta2-Sympathomimetika_inhalativ_Eingr_Olodaterol_Gr1_BAnz.pdf2026-08-26T07:56:53.041Z"15d2639d400d2c32939cb81b094e7025"64167STANDARD2206203922062039Normalkb-subset/2014-07-17_AM-RL-IX-XII_Beta2-Sympathomimetika_inhalativ_Eingr_Olodaterol_Gr1_TrG.pdf2026-08-26T07:56:53.055Z"9e3791157df340a908d9b4ccb2328602"6796013STANDARD2206203922062039Normalkb-subset/2014-07-17_AM-RL-XII_Macitentan_2014-02-01-D-096_BAnz.pdf2026-08-26T07:56:53.044Z"96e0e44bf6980b89d0b75d9343f17c09"123897STANDARD2206203922062039Normalkb-subset/2014-07-17_AM-RL-XII_Macitentan_2014-02-01-D-096_TrG.pdf2026-08-26T07:56:53.046Z"37a84708256389be2ead0890f22bd8ba"118664STANDARD2206203922062039Normalkb-subset/2014-07-17_AM-RL-XII_Sofosbuvir_2014-02-01-D-091_BAnz.pdf2026-08-26T07:56:53.047Z"9f102fd871503cbab4ff3802e24d2ff9"699617STANDARD2206203922062039Normalkb-subset/2014-07-17_AM-RL-XII_Sofosbuvir_2014-02-01-D-091_TrG.pdf2026-08-26T07:56:53.058Z"ad629c72a797f7aa3c852e522d18386e"171598STANDARD2206203922062039Normalkb-subset/2014-07-22_Wortprotokoll_22-02-2014_Canagliflozin.pdf2026-08-26T07:56:53.070Z"8ea0cb76638d9d485db046790a275d4d"264315STANDARD2206203922062039Normalkb-subset/2014-08-07_AM-RL-XII_Dapagliflozin_Metformin_2014-02-15-D-097_BAnz.pdf2026-08-26T07:56:53.078Z"0240d014c5243088023eb57345b7414b"147763STANDARD2206203922062039Normalkb-subset/2014-08-07_AM-RL-XII_Dapagliflozin_Metformin_2014-02-15-D-097_TrG.pdf2026-08-26T07:56:53.086Z"4ead75c3f07b45f084be5adb719fb810"173151STANDARD2206203922062039Normalkb-subset/2014-08-07_AM-RL-XII_Dolutegravir_2014-02-15-D-099_BAnz.pdf2026-08-26T07:56:53.092Z"934c902ce7a62fac6bb67c5d01d40ba9"233535STANDARD2206203922062039Normalkb-subset/2014-08-07_AM-RL-XII_Dolutegravir_2014-02-15-D-099_TrG.pdf2026-08-26T07:56:53.089Z"356aa6d69430ae2bb0bd62ea39300193"181919STANDARD2206203922062039Normalkb-subset/2014-08-12_Wortprotokoll_end_Cobicistat.pdf2026-08-26T07:56:53.090Z"8a29dd3124f3e755121e48581b097e97"54821STANDARD2206203922062039Normalkb-subset/2014-08-21_35a_Einstellung-Verfahren-Bedaquilin_D-112_BAnz.pdf2026-08-26T07:56:53.115Z"6d25490db1a51e5e4f8710d4049e9553"50248STANDARD2206203922062039Normalkb-subset/2014-08-21_35a_Einstellung-Verfahren-Bedaquilin_D-112_TrG.pdf2026-08-26T07:56:53.113Z"2c0cac576c579c6f61b9b8df7b3815e0"55383STANDARD2206203922062039Normalkb-subset/2014-09-04_AM-RL-XII_Canagliflozin_2014-03-15-D-101.pdf2026-08-26T07:56:53.109Z"fe60ea049c35ddd2c07112269e65052d"165683STANDARD2206203922062039Normalkb-subset/2014-09-04_AM-RL-XII_Canagliflozin_2014-03-15-D-101_TrG.pdf2026-08-26T07:56:53.117Z"e98c03439ad0458b6d910d91f43d9ff9"150599STANDARD2206203922062039Normalkb-subset/2014-09-08_Wortprotokoll_end_Dimethylfumarat.pdf2026-08-26T07:56:53.125Z"3cbe48c4eddd9f07e3f4c83047e6f776"215815STANDARD2206203922062039Normalkb-subset/2014-09-08_Wortprotokoll_end_Insulin_20degludec.pdf2026-08-26T07:56:53.133Z"59474a19b58fc1156b3a37d91108ffe4"101232STANDARD2206203922062039Normalkb-subset/2014-09-08_Wortprotokoll_end_Riociguat.pdf2026-08-26T07:56:53.138Z"6971add05902d7b598c90ec9d17dfee6"168703STANDARD2206203922062039Normalkb-subset/2014-09-18_AM-RL-XII_Cobicistat_2014-04-01-D-104_BAnz.pdf2026-08-26T07:56:53.146Z"bdb0781a876ad5fc4bc3514ed9ec95ba"97433STANDARD2206203922062039Normalkb-subset/2014-09-18_AM-RL-XII_Cobicistat_2014-04-01-D-104_TrG.pdf2026-08-26T07:56:53.151Z"a09f23a40b3373b75d08c43a14e3cd9f"81398STANDARD2206203922062039Normalkb-subset/2014-09-22_Wortprotokoll_End_Ruxolitinib.pdf2026-08-26T07:56:53.152Z"f7cba5f0128158d644d245bd26fbd567"115394STANDARD2206203922062039Normalkb-subset/2014-09-22_Wortprotokoll_Perampanel.pdf2026-08-26T07:56:53.153Z"b0a18d21886144cc79d30166e08ea5cc"211593STANDARD2206203922062039Normalkb-subset/2014-09-22_Wortprotokoll_end_Chols_C3_A4ure.pdf2026-08-26T07:56:53.165Z"14a865e985b1e13915994d19284575e3"150548STANDARD2206203922062039Normalkb-subset/2014-10-06_Wortprotokoll_end_Elosulfase_alfa.pdf2026-08-26T07:56:53.176Z"696dc9aa849f8170930fec94b4b6d306"178442STANDARD2206203922062039Normalkb-subset/2014-10-06_Wortprotokoll_end_Mirabegron.pdf2026-08-26T07:56:53.178Z"24f9e544065623ada4bb1c82783cf653"221013STANDARD2206203922062039Normalkb-subset/2014-10-06_Wortprotokoll_end_Simeprevir.pdf2026-08-26T07:56:53.180Z"79f630a6e18802d3a2fc950b9b631b57"169167STANDARD2206203922062039Normalkb-subset/2014-10-06_Wortprotokoll_end_lebende_20Larven_20von_20Lucilia_20sericata.pdf2026-08-26T07:56:53.186Z"880dfdd285d89e7a8a7412edabae68ae"71305STANDARD2206203922062039Normalkb-subset/2014-10-16_AM-RL-XII_Dimethylfumarat_2014-05-01-D-100.pdf2026-08-26T07:56:53.188Z"79be9bd422055302699bcc0497abf1c7"76037STANDARD2206203922062039Normalkb-subset/2014-10-16_AM-RL-XII_Dimethylfumarat_2014-05-01-D-100_TrG.pdf2026-08-26T07:56:53.198Z"80b3373e859286477ca6a378a8017c41"192543STANDARD2206203922062039Normalkb-subset/2014-10-16_AM-RL-XII_Insulin_20degludec_2014-05-01-D-109.pdf2026-08-26T07:56:53.203Z"b358b4e78b9f0b09f62f26860c114a12"200466STANDARD2206203922062039Normalkb-subset/2014-10-16_AM-RL-XII_Insulin_20degludec_2014-05-01-D-109_TrG.pdf2026-08-26T07:56:53.203Z"cdb8967d11536d7a1eb78fa940443b98"156167STANDARD2206203922062039Normalkb-subset/2014-10-16_AM-RL-XII_Riociguat_2014-05-01-D-103.pdf2026-08-26T07:56:53.215Z"a77a2913e0d4282bb409aa053ee09d4e"132904STANDARD2206203922062039Normalkb-subset/2014-10-16_AM-RL-XII_Riociguat_2014-05-01-D-103_TrG.pdf2026-08-26T07:56:53.220Z"d593e69a80cedc4e80d520a63f707a6d"135013STANDARD2206203922062039Normalkb-subset/2014-10-28_Wortprotokoll_end_Insulin_20degludec_28nAWG_29.pdf2026-08-26T07:56:53.216Z"dda471ac6055e513d99650d550dbb6c5"112197STANDARD2206203922062039Normalkb-subset/2014-10-28_Wortprotokoll_end_Siltuximab.pdf2026-08-26T07:56:53.247Z"bf1ca2f4fcbd5072722d5b46ba3ae26b"164387STANDARD2206203922062039Normalkb-subset/2014-11-06_AM-RL-XII_Cholsaeure_2014-05-15-D-105_BAnz.pdf2026-08-26T07:56:53.242Z"5847a6c4efffce4f2c3c8d6345e261d3"110512STANDARD2206203922062039Normalkb-subset/2014-11-06_AM-RL-XII_Cholsaeure_2014-05-15-D-105_TrG.pdf2026-08-26T07:56:53.242Z"974b5f0dfc751ce8fcbba08d365076da"98221STANDARD2206203922062039Normalkb-subset/2014-11-06_AM-RL-XII_Perampanel_2014-05-15-D-106.pdf2026-08-26T07:56:53.248Z"7527b3fc0b40d93e3a225be88e18fb90"100659STANDARD2206203922062039Normalkb-subset/2014-11-06_AM-RL-XII_Perampanel_2014-05-15-D-106_TrG.pdf2026-08-26T07:56:53.252Z"434c654c706cc534f867285e82ebfc65"106035STANDARD2206203922062039Normalkb-subset/2014-11-06_AM-RL-XII_Ruxolitinib_2014-05-15-D-108.pdf2026-08-26T07:56:53.251Z"5bb4e42e4c9e9c59866cc3e37e24a63b"120625STANDARD2206203922062039Normalkb-subset/2014-11-06_AM-RL-XII_Ruxolitinib_2014-05-15-D-108_TrG.pdf2026-08-26T07:56:53.256Z"ea49f738e3a6fff25f436b995d82ed64"119113STANDARD2206203922062039Normalkb-subset/2014-11-11_Wortprotokoll_end_Fingolimod_bf.pdf2026-08-26T07:56:53.263Z"0c1b4735acfa36aea555f69b739236dc"137214STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Elosulfase_20alfa_2014-06-01-D-114.pdf2026-08-26T07:56:53.266Z"3a0a41e23847f6966c5c85364f38c6b1"104044STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Elosulfase_20alfa_2014-06-01-D-114_TrG.pdf2026-08-26T07:56:53.284Z"8c180616370d03ac5b0cf98e58baf9ff"122962STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Lebende_20Larven_2014-06-01-D-115.pdf2026-08-26T07:56:53.286Z"5a92f68fddb19e21c0ef0585ee6e7c1b"82384STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Lebende_20Larven_2014-06-01-D-115_TrG.pdf2026-08-26T07:56:53.290Z"e25c57bc84514d5d660af8d95a00f0f5"78568STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Mirabegron_2014-06-01-D-110.pdf2026-08-26T07:56:53.306Z"431a5ce057db32ea7c77ea9457238479"109184STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Mirabegron_2014-06-01-D-110_TrG.pdf2026-08-26T07:56:53.310Z"988d289d06ebbf011d5eb47eb045c95d"90743STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Simeprevir_2014-06-01-D-113.pdf2026-08-26T07:56:53.324Z"52f911f09c3a80c7cf3883921c561ca9"361963STANDARD2206203922062039Normalkb-subset/2014-11-20_AM-RL-XII_Simeprevir_2014-06-01-D-113_TrG.pdf2026-08-26T07:56:53.316Z"808f99458dfd203f2aa988e9f7703ef6"206709STANDARD2206203922062039Normalkb-subset/2014-11-25_Wortprotokoll_end_Umeclidinium_Vilanterol.pdf2026-08-26T07:56:53.320Z"d1e7e4ddb5bf9594809d2e4c7df17146"198614STANDARD2206203922062039Normalkb-subset/2014-11-25_Wortprotokoll_end_Vedolizumab.pdf2026-08-26T07:56:53.317Z"dfba7bc9e86c203ab7694f658add7d49"229996STANDARD2206203922062039Normalkb-subset/2014-12-01_Wortprotokoll_D-145_Vildagliptin_erneute_NB.pdf2026-08-26T07:56:53.325Z"c99038a791a1e24aaa94610820c032c0"150842STANDARD2206203922062039Normalkb-subset/2014-12-04_AM-RL-XII_Insulin-degludec_nAWG_2014-06-15-D-118.pdf2026-08-26T07:56:53.331Z"485ff340fa3f55cabdf03390870d3331"98571STANDARD2206203922062039Normalkb-subset/2014-12-04_AM-RL-XII_Insulin-degludec_nAWG_2014-06-15-D-118_TrG.pdf2026-08-26T07:56:53.331Z"cbe68da4bb3753fbaa76a0c18f29d00a"93460STANDARD2206203922062039Normalkb-subset/2014-12-04_AM-RL-XII_Siltuximab_2014-06-15-D-119.pdf2026-08-26T07:56:53.353Z"6ac20a1181187c0a16b0b922a2b69b7d"155177STANDARD2206203922062039Normalkb-subset/2014-12-04_AM-RL-XII_Siltuximab_2014-06-15-D-119_TrG.pdf2026-08-26T07:56:53.353Z"98da77548c22b6df4070056e41d0d06a"152715STANDARD2206203922062039Normalkb-subset/2014-12-09_Wortprotokoll_15-12-2014_Cabozantinib.pdf2026-08-26T07:56:53.357Z"10df09b3b8801a2640f8b020bd55fc45"174657STANDARD2206203922062039Normalkb-subset/2014-12-09_Wortprotokoll_end_Eribulin_bf.pdf2026-08-26T07:56:53.374Z"95cef41d9418f8746b6d2e5407efe52f"213317STANDARD2206203922062039Normalkb-subset/2014-12-18_AM-RL-XII_Fingolimod_nAWG_2014-07-01-D-116.pdf2026-08-26T07:56:53.375Z"2d54cb1348b6aab7d866513966390dc5"203245STANDARD2206203922062039Normalkb-subset/2014-12-18_AM-RL-XII_Fingolimod_nAWG_2014-07-01-D-116_TrG.pdf2026-08-26T07:56:53.381Z"e11727832d72fad353ab4a561f7d6b70"135863STANDARD2206203922062039Normalkb-subset/2014-12-19_Wortprotokoll_Canagliflozin-Metformin_D-124.pdf2026-08-26T07:56:53.453Z"6a046d4a61d054ce52daeb59a7fc40da"65403STANDARD2206203922062039Normalkb-subset/2014-12-19_Wortprotokoll_end_Empagliflozin_bf.pdf2026-08-26T07:56:53.396Z"20a852736381a2a4fa9f864670737da7"201963STANDARD2206203922062039Normalkb-subset/2014-12-19_Wortprotokoll_end_Obinutuzumab_bf.pdf2026-08-26T07:56:53.398Z"c288e90f7b76402d2f85df60d263d5e2"123208STANDARD2206203922062039Normalkb-subset/2015-01-08_AM-RL-XII_Umeclidinium-Vilanterol_2014-07-15-D-117.pdf2026-08-26T07:56:53.398Z"d1ab8202c1260288d4057b11618f46b0"127260STANDARD2206203922062039Normalkb-subset/2015-01-08_AM-RL-XII_Umeclidinium-Vilanterol_2014-07-15-D-117_TrG.pdf2026-08-26T07:56:53.399Z"393241f49091f60e7edab965ff3d3657"143146STANDARD2206203922062039Normalkb-subset/2015-01-08_AM-RL-XII_Vedolizumab_2014-07-15-D-122.pdf2026-08-26T07:56:53.404Z"468f9d85cdd2096ea2d8850eda0531d4"151732STANDARD2206203922062039Normalkb-subset/2015-01-08_AM-RL-XII_Vedolizumab_2014-07-15-D-122_TrG.pdf2026-08-26T07:56:53.413Z"8209080f902ebacc0ca8b14d224387c1"174660STANDARD2206203922062039Normalkb-subset/2015-01-12_Wortprotokoll_Nalmefen.pdf2026-08-26T07:56:53.423Z"6d499b2bec70007be1d9a2f66cdbbb0f"146417STANDARD2206203922062039Normalkb-subset/2015-01-12_Wortprotokoll_Regorafenib_nAWG.pdf2026-08-26T07:56:53.429Z"42dfaf1d373eb8af44b538e4b9e44ba7"87438STANDARD2206203922062039Normalkb-subset/2015-01-12_Wortprotokoll_end_Daclatasvir.pdf2026-08-26T07:56:53.443Z"3d9520e5c17326c73e96b8534efde94f"122959STANDARD2206203922062039Normalkb-subset/2015-01-12_Wortprotokoll_end_Ivacaftor-nAWG.pdf2026-08-26T07:56:53.445Z"b282195bcd3c819cb9d766d6daa02851"95189STANDARD2206203922062039Normalkb-subset/2015-01-12_Wortprotokoll_end_Propranolol.pdf2026-08-26T07:56:53.456Z"627ddf80b34a72159fbabaecfa91100f"123356STANDARD2206203922062039Normalkb-subset/2015-01-22_AM-RL-XII_Cabozantinib_2014-08-01-D-121.pdf2026-08-26T07:56:53.473Z"9719ee19518b1d8794884cd3cce3b000"148973STANDARD2206203922062039Normalkb-subset/2015-01-22_AM-RL-XII_Cabozantinib_2014-08-01-D-121_TrG.pdf2026-08-26T07:56:53.464Z"002d59f59f4941eafc8c9a7e0316f589"115611STANDARD2206203922062039Normalkb-subset/2015-01-22_AM-RL-XII_Eribulin_2014-08-01-D-125.pdf2026-08-26T07:56:53.466Z"b54587b4b74c25f89dc4dc276d1663bc"186540STANDARD2206203922062039Normalkb-subset/2015-01-22_AM-RL-XII_Eribulin_2014-08-01-D-125_TrG.pdf2026-08-26T07:56:53.469Z"7ab6a692df77d7830e28a0f18ee58694"156306STANDARD2206203922062039Normalkb-subset/2015-01-27_Wortprotokoll_end_Aflibercept.pdf2026-08-26T07:56:53.487Z"f5c7affb2b3ff4bcda9f10c8d6ff1c12"221711STANDARD2206203922062039Normalkb-subset/2015-02-05_AM-RL-XII_CanagliflozinMetformin_2014-08-15-D-124.pdf2026-08-26T07:56:53.484Z"3fc9ea02398590c059d584af237c6098"130317STANDARD2206203922062039Normalkb-subset/2015-02-05_AM-RL-XII_CanagliflozinMetformin_2014-08-15-D-124_TrG.pdf2026-08-26T07:56:53.490Z"8262754f556c6b0c636f6bcbfb8d61d1"159009STANDARD2206203922062039Normalkb-subset/2015-02-05_AM-RL-XII_Empagliflozin_2014-08-15-D-123.pdf2026-08-26T07:56:53.505Z"f45444edee1e59b8644f25a0057d6e7e"194908STANDARD2206203922062039Normalkb-subset/2015-02-05_AM-RL-XII_Empagliflozin_2014-08-15-D-123_TrG.pdf2026-08-26T07:56:53.501Z"2c8e3586513e67ec9e122d37623ef722"172742STANDARD2206203922062039Normalkb-subset/2015-02-05_AM-RL-XII_Obinutuzumab_2014-08-15-D-120.pdf2026-08-26T07:56:53.516Z"2ff04c16d96d2167e8a6db863ae6d6de"109415STANDARD2206203922062039Normalkb-subset/2015-02-05_AM-RL-XII_Obinutuzumab_2014-08-15-D-120_TrG.pdf2026-08-26T07:56:53.520Z"d5b06f26679efd724368f9418cf42a21"120797STANDARD2206203922062039Normalkb-subset/2015-02-09_Wortprotokoll_end_Albiglutid.pdf2026-08-26T07:56:53.527Z"cf7d59a0006562e81bb54ddab24207c7"120506STANDARD2206203922062039Normalkb-subset/2015-02-09_Wortprotokoll_end_Dolutegravir_Abacavir_Lamivudin.pdf2026-08-26T07:56:53.536Z"38d97806922806a38db28d78c6a58d03"88859STANDARD2206203922062039Normalkb-subset/2015-02-09_Wortprotokoll_end_Idelalisib.pdf2026-08-26T07:56:53.534Z"689b6bddffa9fba917647f02c8e22685"166191STANDARD2206203922062039Normalkb-subset/2015-02-09_Wortprotokoll_end_Sipuleucel-T.pdf2026-08-26T07:56:53.533Z"fbe0bd281743691d3f74426774b66aa2"118578STANDARD2206203922062039Normalkb-subset/2015-02-09_Wortprotokoll_end_Sucroferric_Oxyhydroxide.pdf2026-08-26T07:56:53.548Z"4c2c3c4ff04fdb86dbd4b962ac8f9651"104243STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Apixaban_2014-09-01-D-126.pdf2026-08-26T07:56:53.550Z"bde5ebb328c659f9c91e5498ef38d84a"148426STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Apixaban_2014-09-01-D-126_TrG.pdf2026-08-26T07:56:53.552Z"bace1300328e759785f31ecb00acc142"137271STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Daclastavirr_2014-09-01-D-129.pdf2026-08-26T07:56:53.557Z"7e4070dcfd8567087d9cda5c73019f9e"297475STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Daclastavirr_2014-09-01-D-129_TrG.pdf2026-08-26T07:56:53.567Z"de5e592b7060e7c77e162f4a19e2fc30"172166STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Ivacaftor-nAWG_2014-09-01-D-133.pdf2026-08-26T07:56:53.570Z"fb4a6ed95778836a275d331ca939124b"83662STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Ivacaftor-nAWG_2014-09-01-D-133_TrG.pdf2026-08-26T07:56:53.584Z"db57bdc7e81ccc42f5fc3cd0d6b394fb"107453STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Nalmefen_2014-09-01-D-127.pdf2026-08-26T07:56:53.587Z"2ee7ba8195f8761f73af8b7056d5fd65"75703STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Nalmefen_2014-09-01-D-127_TrG.pdf2026-08-26T07:56:53.599Z"c6cf596d472d1891e79d79ff98527671"110143STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Propranolol_2014-09-01-D-128.pdf2026-08-26T07:56:53.602Z"a71189c7a4b74c7c2d58be9559dc563c"111526STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Propranolol_2014-09-01-D-128_TrG.pdf2026-08-26T07:56:53.606Z"8fdb51b5422b78fbd73d8b878f5fbb60"139179STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Regorafenib-nAWG_2014-09-01-D-134.pdf2026-08-26T07:56:53.612Z"274f147111284c69ed01c71c45a4b266"57379STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Regorafenib-nAWG_2014-09-01-D-134_TrG.pdf2026-08-26T07:56:53.612Z"7a9e80014649245227a2c99c89292b5c"86071STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Teduglutid_2014-09-01-D-130.pdf2026-08-26T07:56:53.617Z"3d140bf067451002a806d9ff55528db9"107527STANDARD2206203922062039Normalkb-subset/2015-02-19_AM-RL-XII_Teduglutid_2014-09-01-D-130_TrG.pdf2026-08-26T07:56:53.615Z"56d9bcebab6a164471a24566830a5b21"95521STANDARD2206203922062039Normalkb-subset/2015-03-05_Aflibercept_nAWG_2014-09-15-D-137.pdf2026-08-26T07:56:53.619Z"c8a11887351108b66dfdbe54ca7c7e2b"177759STANDARD2206203922062039Normalkb-subset/2015-03-05_Aflibercept_nAWG_2014-09-15-D-137_TrG.pdf2026-08-26T07:56:53.641Z"be2c5d9573a4ef459f742fd9a7d6e513"140209STANDARD2206203922062039Normalkb-subset/2015-03-09_Wortprotokoll_Alipogentiparvovec.pdf2026-08-26T07:56:53.640Z"c95706e5d9d27205911fe5adab8cf675"107589STANDARD2206203922062039Normalkb-subset/2015-03-09_Wortprotokoll_Ibrutinib.pdf2026-08-26T07:56:53.659Z"45d9463e5d54d9502440d7c1b7e9da72"165611STANDARD2206203922062039Normalkb-subset/2015-03-09_Wortprotokoll_Lurasidon.pdf2026-08-26T07:56:53.665Z"4ef2e2be4b0d72b0ab2e2b90f069430c"69536STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Albiglutid_2014-10-01-D-132.pdf2026-08-26T07:56:53.668Z"71be93282fbcb3b1cbe13ecec9cd8fb6"209238STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Albiglutid_2014-10-01-D-132_TrG.pdf2026-08-26T07:56:53.675Z"fc53050c89853e7b46e425cad87a41ef"172778STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Dolutegravir-Kombi_2014-10-01-D-131.pdf2026-08-26T07:56:53.680Z"d35c2457da1441c58a9c7566cf48af64"180086STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Dolutegravir-Kombi_2014-10-01-D-131_TrG.pdf2026-08-26T07:56:53.676Z"8868db30cd7a5c7a2d42aac6f033c52a"171874STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Idelalisib_2014-10-01-D-135.pdf2026-08-26T07:56:53.681Z"3ea7f84ef38ea4b994445929b7abf21b"156477STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Idelalisib_2014-10-01-D-135_TrG.pdf2026-08-26T07:56:53.682Z"dfd0468dbcf172f7abfa1e9d3e71abf7"197922STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Sipuleucel-T_2014-10-01-D-139.pdf2026-08-26T07:56:53.684Z"de6c6de1a41778eb9d9eab55f0e6efcc"123120STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Sipuleucel-T_2014-10-01-D-139_TrG.pdf2026-08-26T07:56:53.695Z"0062e7ef34702ef156ff34baf54326ca"153278STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Sucroferric_2014-10-01-D-136.pdf2026-08-26T07:56:53.705Z"4afea3487ac5f9a0092117fe4eb1fb1f"105879STANDARD2206203922062039Normalkb-subset/2015-03-19_AM-RL-XII_Sucroferric_2014-10-01-D-136_TrG.pdf2026-08-26T07:56:53.715Z"54d2c89cf553de9eec555f79dd49d609"130122STANDARD2206203922062039Normalkb-subset/2015-04-07_Wortprotokoll_07-04-2015_Ataluren.pdf2026-08-26T07:56:53.732Z"6320e597f3ffbe252f23c32482dc7251"109945STANDARD2206203922062039Normalkb-subset/2015-04-07_Wortprotokoll_end_Ledipasvir-Sofosbuvir.pdf2026-08-26T07:56:53.727Z"56c0bb7806666f2b93539fd4783eadf7"138379STANDARD2206203922062039Normalkb-subset/2015-04-16_AM-RL-XII_Ibrutinib_2014-11-01-D-141.pdf2026-08-26T07:56:53.732Z"dbe2a1ef15555847910591bf393b79fd"141946STANDARD2206203922062039Normalkb-subset/2015-04-16_AM-RL-XII_Ibrutinib_2014-11-01-D-141_TrG.pdf2026-08-26T07:56:53.737Z"82a1a0d9d5f9e8371f274127e14b83ea"145399STANDARD2206203922062039Normalkb-subset/2015-04-16_AM-RL-XII_Lurasidon_2014-11-01-D-142.pdf2026-08-26T07:56:53.742Z"e2288d974f8d95440c6cbaf8c284febd"110677STANDARD2206203922062039Normalkb-subset/2015-04-16_AM-RL-XII_Lurasidon_2014-11-01-D-142_TrG.pdf2026-08-26T07:56:53.745Z"75405e75a3bf761ee3f2d61d32b1fd09"99843STANDARD2206203922062039Normalkb-subset/2015-05-07_AM-RL-XII_Simoctocog_20alfa_2014-11-15-D-140.pdf2026-08-26T07:56:53.747Z"e6e2228314d03919190cbc360f2f0070"114378STANDARD2206203922062039Normalkb-subset/2015-05-07_AM-RL-XII_Simoctocog_20alfa_2014-11-15-D-140_TrG.pdf2026-08-26T07:56:53.746Z"2e4c38f8f0fe77b35994069c4711eba5"114709STANDARD2206203922062039Normalkb-subset/2015-05-11_Wortprotokoll_Pasireotid.pdf2026-08-26T07:56:53.753Z"ba3beecd81074d71e8cebe139ccfadb9"107697STANDARD2206203922062039Normalkb-subset/2015-05-11_Wortprotokoll_end_Enzalutamid_nAWG.PDF2026-08-26T07:56:53.777Z"bb79ebb371ffd1cac5a94b7e22a75530"150148STANDARD2206203922062039Normalkb-subset/2015-05-11_Wortprotokoll_end_Nintedanib.pdf2026-08-26T07:56:53.785Z"88635372846938fe3e55fc0dbe50fbc6"132064STANDARD2206203922062039Normalkb-subset/2015-05-11_Wortprotokoll_end_Tafluprost-Timolol.pdf2026-08-26T07:56:53.785Z"4f3fed53203c054a335524589b88cb70"96438STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Alipogentiparvovec_2014-11-01-D-138.pdf2026-08-26T07:56:53.791Z"0903d4cbc370b9a647086de0f4e3b8bd"81487STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Alipogentiparvovec_2014-11-01-D-138_TrG.pdf2026-08-26T07:56:53.801Z"e5cec72e2164d977e281245de704fd13"106069STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Ataluren_2012-01-D-149.pdf2026-08-26T07:56:53.802Z"5fdd53934c760ee07631a3b7387fed66"121068STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Ataluren_2012-01-D-149_TrG.pdf2026-08-26T07:56:53.813Z"d21018465f3a3b1a3dd5d749694e4ac3"118064STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Ledipasvir-Sofosbuvir_2014-12-01-D-143.pdf2026-08-26T07:56:53.804Z"6b3a675d43ed8d64ec1701b471c7bec5"346302STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Ledipasvir-Sofosbuvir_2014-12-01-D-143_TrG.pdf2026-08-26T07:56:53.810Z"ae3e6e7bb0deb60a0845a8008041e021"240862STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Vildagliptin_2014-12-01-D-145.pdf2026-08-26T07:56:53.810Z"b5f98d45db87146651f3cacfaeb2fc8e"108979STANDARD2206203922062039Normalkb-subset/2015-05-21_AM-RL-XII_Vildagliptin_2014-12-01-D-145_TrG.pdf2026-08-26T07:56:53.813Z"395a7d0c05ce1063295705f03ba78827"153902STANDARD2206203922062039Normalkb-subset/2015-06-08_Wortprotokoll_end_08-06-2015_Dulaglutid.pdf2026-08-26T07:56:53.831Z"206cfcfa871dcfa6ad71fd905033c31a"126307STANDARD2206203922062039Normalkb-subset/2015-06-08_Wortprotokoll_end_Dasabuvir-Ombitasvir-etc-2.pdf2026-08-26T07:56:53.845Z"56d39389366e15b4792503c45634e472"123259STANDARD2206203922062039Normalkb-subset/2015-06-08_Wortprotokoll_end_Dasabuvir-Ombitasvir-etc.pdf2026-08-26T07:56:53.850Z"d3fd7e446f048f955a7d27b8376553c0"117577STANDARD2206203922062039Normalkb-subset/2015-06-08_Wortprotokoll_end_Ramucirumab.pdf2026-08-26T07:56:53.855Z"143e3cad2384277463a515d7212e8dbe"86088STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Enzalutamid_nAWG_2015-01-01-D-146.pdf2026-08-26T07:56:53.857Z"0daf10affedde78c43dabfe701910329"136104STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Enzalutamid_nAWG_2015-01-01-D-146_TrG.pdf2026-08-26T07:56:53.885Z"de23deae24a759db8944538c71e4acde"124209STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Nintedanib_2015-01-01-D-147.pdf2026-08-26T07:56:53.892Z"80595e7ad391b40ef8523379b63cfd25"204508STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Nintedanib_2015-01-01-D-147_TrG.pdf2026-08-26T07:56:53.893Z"a2baa0f2073ffe4337e9756faf5a900f"153191STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Pasireotid_nAWG_2015-01-01-D-148.pdf2026-08-26T07:56:53.896Z"8f326ff1a85fabc40560e59cbc29d8f0"124033STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Pasireotid_nAWG_2015-01-01-D-148_TrG.pdf2026-08-26T07:56:53.895Z"4d7e928e070fab6ad970c6d7fd15b9c8"117369STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Tafluprost_Timolol_2015-01-01-D-144.pdf2026-08-26T07:56:53.895Z"87e1a0118a79769b17a842c59b5b28cf"137747STANDARD2206203922062039Normalkb-subset/2015-06-18_AM-RL-XII_Tafluprost_Timolol_2015-01-01-D-144_TrG.pdf2026-08-26T07:56:53.902Z"66187cd82de28889e215f884fcff1c64"154643STANDARD2206203922062039Normalkb-subset/2015-06-23_Wortprotokoll_26-06-2015_Apremilast.pdf2026-08-26T07:56:53.901Z"c9157713d5e685061875377ea38bf372"169629STANDARD2206203922062039Normalkb-subset/2015-07-07_Wortprotokoll_Insulin_20degludec-nAWG.PDF2026-08-26T07:56:53.904Z"91a01b28eef3952d4bfcfbf715dadcb4"116923STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Aclidiniumbromid-Formoterol_2015-02-01-D-155.pdf2026-08-26T07:56:53.917Z"042e4b3924b77a7e4eb6427439f0a175"184770STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Aclidiniumbromid-Formoterol_2015-02-01-D-155_TrG.pdf2026-08-26T07:56:53.923Z"2db427ee286715b64d61ef37302411c8"129713STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Albiglutid_2014-10-01-D-132_Aenderung-Patientengruppen_BAnz.pdf2026-08-26T07:56:53.927Z"f29907cbfdf01fb7696ffa0085adc33a"567656STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Dasabuvir_2015-02-01-D-152.pdf2026-08-26T07:56:53.954Z"4c30326b24ecc22b51986e0fe4556f23"292995STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Dasabuvir_2015-02-01-D-152_TrG.pdf2026-08-26T07:56:53.961Z"b75cd00b6e5c8921698514ea01683836"213447STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Dulaglutid_2015-02-01-D-154.pdf2026-08-26T07:56:53.961Z"686f87a60eb9fe54e603b86e34bdb67e"283781STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Dulaglutid_2015-02-01-D-154_TrG.pdf2026-08-26T07:56:53.964Z"406d5b9889ea44958287eddb8774dd6e"269605STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Ombitasvir-Kombi_2015-02-01-D-153.pdf2026-08-26T07:56:53.969Z"1f7a5d80db6d5a5c5650a0091242fbb3"339983STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Ombitasvir-Kombi_2015-02-01-D-153_TrG.pdf2026-08-26T07:56:53.966Z"590e03c160fb5fbb1e217043b704dbbf"230730STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Ramucirumab_2015-02-01-D-150.pdf2026-08-26T07:56:53.982Z"265d8da1559fe055b3142e5e4c342d85"173803STANDARD2206203922062039Normalkb-subset/2015-07-16_AM-RL-XII_Ramucirumab_2015-02-01-D-150_TrG.pdf2026-08-26T07:56:53.976Z"c71b6f7b053cc23fdec3c0d71468718b"154397STANDARD2206203922062039Normalkb-subset/2015-07-28_Wortprotokoll_end_Aflibercept.pdf2026-08-26T07:56:53.982Z"5a34c0c4c290996add103166db7be5a5"76833STANDARD2206203922062039Normalkb-subset/2015-07-28_Wortprotokoll_end_Nintedanib.pdf2026-08-26T07:56:53.984Z"d07bbb82268c1d22ef5e362adc783ddd"149417STANDARD2206203922062039Normalkb-subset/2015-08-06-Wortprotokoll_end_Aclidiniumbromid-Formoterol.pdf2026-08-26T07:56:53.981Z"308489dd7a251552d297ce4d62ab59a0"73451STANDARD2206203922062039Normalkb-subset/2015-08-06_AM-RL-XII_Apremilast_2015-02-15-D-151.pdf2026-08-26T07:56:53.997Z"1fc7475573c738268b78350650c328fb"105457STANDARD2206203922062039Normalkb-subset/2015-08-06_AM-RL-XII_Apremilast_2015-02-15-D-151_TrG.pdf2026-08-26T07:56:54.026Z"493a78b94fddb2c649322a95e352d49c"133942STANDARD2206203922062039Normalkb-subset/2015-08-11_Wortprotokoll_end_Eliglustat.pdf2026-08-26T07:56:54.024Z"a8edaec40a0d9a4e4bef38b7d6e70d45"147884STANDARD2206203922062039Normalkb-subset/2015-08-11_Wortprotokoll_end_Fingolimod.pdf2026-08-26T07:56:54.038Z"69a49f4fc45a911327a6936e7330acac"154160STANDARD2206203922062039Normalkb-subset/2015-08-20_AM-RL-XII_Insulin-degludec_nAWG-2015-03-01-D-158.pdf2026-08-26T07:56:54.028Z"890a01133db97b4238f23e69ef2be217"193038STANDARD2206203922062039Normalkb-subset/2015-08-20_AM-RL-XII_Insulin-degludec_nAWG-2015-03-01-D-158_TrG.pdf2026-08-26T07:56:54.036Z"365b64de4083e35e329816733bddb710"168257STANDARD2206203922062039Normalkb-subset/2015-09-01_Wortprotokoll_end_Ruxolitinib.pdf2026-08-26T07:56:54.035Z"fa6607b1e091da34ad6919befbb4377e"106521STANDARD2206203922062039Normalkb-subset/2015-09-03_AM-RL-XII_Aflibercept_nAWG_2015-03-15-D-160.pdf2026-08-26T07:56:54.043Z"3dd53eedd1ed6698acba984e45ac3e9f"76685STANDARD2206203922062039Normalkb-subset/2015-09-03_AM-RL-XII_Aflibercept_nAWG_2015-03-15-D-160_TrG.pdf2026-08-26T07:56:54.052Z"ac64eb29fdbec847eb06c8582d802dac"90073STANDARD2206203922062039Normalkb-subset/2015-09-03_AM-RL-XII_Nintedanib_nAWG_2015-03-15-D-156.pdf2026-08-26T07:56:54.054Z"3b4c7131cd8ce35f23b829fd63a023fc"179715STANDARD2206203922062039Normalkb-subset/2015-09-03_AM-RL-XII_Nintedanib_nAWG_2015-03-15-D-156_TrG.pdf2026-08-26T07:56:54.051Z"16d3cd92a357d5c1242ef0381ef9e349"112898STANDARD2206203922062039Normalkb-subset/2015-09-08_Wortprotokoll_Insulin_20degludec_Liraglutid_2015-05-01-D-165_fi....pdf2026-08-26T07:56:54.056Z"d53dabec47e24c13441bc43802b213d5"94980STANDARD2206203922062039Normalkb-subset/2015-09-08_Wortprotokoll_end_Vortioxetin.pdf2026-08-26T07:56:54.062Z"86d4dbc66fc1b5fb0aec742de44e9472"222997STANDARD2206203922062039Normalkb-subset/2015-09-22_Wortprotokoll_Afatinib.pdf2026-08-26T07:56:54.087Z"bd3827dad18c10b7cbd0e3dca99d6abb"163371STANDARD2206203922062039Normalkb-subset/2015-09-22_Wortprotokoll_Safinamid_2015-05-15-D-168.pdf2026-08-26T07:56:54.088Z"5088bf4c4fedec82a0f8cc50d9e9cd19"147228STANDARD2206203922062039Normalkb-subset/2015-10-01_AM-RL-XII_2015-04-01-D-157_Fingolimod-Abl-Befr.pdf2026-08-26T07:56:54.090Z"515a1f75e3e8fd36d4ea4d1af2bc7a6e"187824STANDARD2206203922062039Normalkb-subset/2015-10-01_AM-RL-XII_2015-04-01-D-157_Fingolimod-Abl-Befr_TrG.pdf2026-08-26T07:56:54.100Z"953e83bc443ba9207935d0065468b3d9"196665STANDARD2206203922062039Normalkb-subset/2015-10-01_AM-RL-XII_Eliglustat_2015-04-01-D-159.pdf2026-08-26T07:56:54.102Z"8f74aceff59c0d10f4f6fbb14ab436a9"92084STANDARD2206203922062039Normalkb-subset/2015-10-01_AM-RL-XII_Eliglustat_2015-04-01-D-159_TrG.pdf2026-08-26T07:56:54.114Z"87fae9512f73c2049dc6f5520519ce13"93183STANDARD2206203922062039Normalkb-subset/2015-10-05-Wortprotokoll_2015-06-01-D-166_Olaparib.pdf2026-08-26T07:56:54.113Z"222f819fc5f3e261e95ab381fef425d1"184123STANDARD2206203922062039Normalkb-subset/2015-10-05_Wortprotokoll_D-170_Ivermectin.pdf2026-08-26T07:56:54.113Z"7720447679f3eafb38fdf9ec748cd34b"88482STANDARD2206203922062039Normalkb-subset/2015-10-05_Wortprotokoll_Secukinumab_2015-06-01-D-167.pdf2026-08-26T07:56:54.121Z"fe2f3c8deca57bbed4142eb58c012b9d"121872STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Einstellung-Ibrutinib_2015-08-01-D-178_BAnz.pdf2026-08-26T07:56:54.123Z"74781f150414ca242ed154de96330cfc"482897STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Einstellung-Ibrutinib_2015-08-01-D-178_TrG.pdf2026-08-26T07:56:54.131Z"fa899abafb7f8b5b26066e8d925c0a81"53173STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Insulin-degludec_Liraglutid_2015-05-15-D-165.pdf2026-08-26T07:56:54.131Z"466210a83bbeb9ee7affc764b8578fe4"164350STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Insulin-degludec_Liraglutid_2015-05-15-D-165_TrG.pdf2026-08-26T07:56:54.154Z"12911a0adf8d7bb66481077ec563b32d"154378STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Ruxolitinib-nAWG_2015-04-15-D-161.pdf2026-08-26T07:56:54.161Z"a3e325d5878b1715b60c195e130c57e6"109214STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Ruxolitinib-nAWG_2015-04-15-D-161_TrG.pdf2026-08-26T07:56:54.163Z"48878938e0459dbd10a563b9cbf9d16f"140424STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Ruxolitinib_Aenderung_2014-05-15-D-108_BAnz.pdf2026-08-26T07:56:54.166Z"5666e877b887c0527e7795a5f4d9594e"579020STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Vortioxetin_2015-05-01-D-162.pdf2026-08-26T07:56:54.172Z"e35f497f069def57185286f3a84dae1b"86335STANDARD2206203922062039Normalkb-subset/2015-10-15_AM-RL-XII_Vortioxetin_2015-05-01-D-162_TrG.pdf2026-08-26T07:56:54.177Z"f02349efe3147e230402fae064287d9c"142951STANDARD2206203922062039Normalkb-subset/2015-10-27_Wortprotokoll_end_Lomitapid.pdf2026-08-26T07:56:54.178Z"eac97bb47c104dcae4aa81dfe16bc709"126635STANDARD2206203922062039Normalkb-subset/2015-11-05_AM-RL-XII_Safinamid_2015-05-15-D-168.pdf2026-08-26T07:56:54.185Z"89284eb1aaf632ff57d1711af823472f"254135STANDARD2206203922062039Normalkb-subset/2015-11-05_AM-RL-XII_Safinamid_2015-05-15-D-168_TrG.pdf2026-08-26T07:56:54.187Z"506a4d7ee1973614d6dca2c98e2d8942"128552STANDARD2206203922062039Normalkb-subset/2015-11-05_AM-TL-XII_Afatinib_2015-05-15-D-163.pdf2026-08-26T07:56:54.195Z"e9fa2436b6681c3c4fd2c80466ad233f"226949STANDARD2206203922062039Normalkb-subset/2015-11-05_AM-TL-XII_Afatinib_2015-05-15-D-163_TrG.pdf2026-08-26T07:56:54.198Z"820567e15f55b39fbb67d3ab13ac2cd1"152745STANDARD2206203922062039Normalkb-subset/2015-11-10_Wortprotokoll_end_Ceritinib.pdf2026-08-26T07:56:54.206Z"8aeecd6d2aeacdb41091b3c1e82b9810"226500STANDARD2206203922062039Normalkb-subset/2015-11-10_Wortprotokoll_end_Lenvatinib.pdf2026-08-26T07:56:54.225Z"7de976716ecffd96f0acb4b569db8fd9"115507STANDARD2206203922062039Normalkb-subset/2015-11-15_Wortprotokoll_Simoctocog_alfa_D-140.pdf2026-08-26T07:56:54.223Z"65d31e0e5e3d374d4fc1ee2b8c4f1d0d"123923STANDARD2206203922062039Normalkb-subset/2015-11-24_Wortprotokoll_end_Belatacept.pdf2026-08-26T07:56:54.234Z"c42bd1c837ba29d218ab1a364752b846"62319STANDARD2206203922062039Normalkb-subset/2015-11-24_Wortprotokoll_end_Nivolumab.pdf2026-08-26T07:56:54.238Z"9a1dec9755c04745e7cdcc54aa5544e6"171369STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Ivermectin_2015-06-01-D-170.pdf2026-08-26T07:56:54.236Z"e2474e04fa4c6c84208d9bdc6661a46c"75748STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Ivermectin_2015-06-01-D-170_TrG.pdf2026-08-26T07:56:54.240Z"348d8e78af6f70f3c56884f1057985d3"74058STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Lomitapid_2015-06-15-D-169.pdf2026-08-26T07:56:54.482Z"5af59bae7121f25be9ea091730ea5ebd"119896STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Lomitapid_2015-06-15-D-169_TrG.pdf2026-08-26T07:56:54.254Z"eccff3c7a2a24253a1aa2b22f2492742"114956STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Olaparib_2015-06-01-D-166.pdf2026-08-26T07:56:54.262Z"221c42de1f214841195f8d2d3cac779f"111159STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Olaparib_2015-06-01-D-166_TrG.pdf2026-08-26T07:56:54.266Z"c418971040de7233a912d6b221c7948f"117778STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Secukinumab_2015-06-01-D167.pdf2026-08-26T07:56:54.268Z"e2fc3c24b51fbc9c2ebab9c5627111d2"212491STANDARD2206203922062039Normalkb-subset/2015-11-27_AM-RL-XII_Secukinumab_2015-06-01-D167_TrG.pdf2026-08-26T07:56:54.278Z"af8c803d23d5f0da49fbe135ad78a81c"160044STANDARD2206203922062039Normalkb-subset/2015-12-08_Wortprotokoll_end_Edoxaban.pdf2026-08-26T07:56:54.290Z"1c3b983a4e60b57f488031a64d3ccc21"158508STANDARD2206203922062039Normalkb-subset/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171.pdf2026-08-26T07:56:54.300Z"32c14706e2f78df0f0e8004446c87f2a"102695STANDARD2206203922062039Normalkb-subset/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171_TrG.pdf2026-08-26T07:56:54.300Z"461dfb911f77fd39411eec220cfb7b2d"131905STANDARD2206203922062039Normalkb-subset/2015-12-17_AM-RL-XII_Lenvatinib_2015-07-01-D-164.pdf2026-08-26T07:56:54.304Z"5d9d85856b6fa9fa3f57afe86a67106d"78075STANDARD2206203922062039Normalkb-subset/2015-12-17_AM-RL-XII_Lenvatinib_2015-07-01-D-164_TrG.pdf2026-08-26T07:56:54.306Z"9fceed4157e493df15e57178f7ab30f2"102289STANDARD2206203922062039Normalkb-subset/2015-12-21_Wortprotokoll_end_Insulin_deglucec-Liraglutid.pdf2026-08-26T07:56:54.310Z"b2f8363a037db75d9400957e1579021e"46396STANDARD2206203922062039Normalkb-subset/2015-12-21_Wortprotokoll_end_Netupitant-Palonosetron.pdf2026-08-26T07:56:54.328Z"df9b021fb9a3cae6bbdf8422b95be757"123867STANDARD2206203922062039Normalkb-subset/2015-12-21_Wortprotokoll_end_Nivolumab_nAWG_2016-07-15.pdf2026-08-26T07:56:54.334Z"2cea3a8fcdaf96cd429eb5dc72b5d881"109369STANDARD2206203922062039Normalkb-subset/2015-12-21_Wortprotokoll_end_Pembrolizumab.pdf2026-08-26T07:56:54.333Z"3ddd93fbc2049733cd26b21097809f11"98150STANDARD2206203922062039Normalkb-subset/2015-12-21_Wortprotokoll_end_Tiotropium-Olodaterol.pdf2026-08-26T07:56:54.331Z"653598d939eb411661748bb951c8f932"180033STANDARD2206203922062039Normalkb-subset/2016-01-07_AM-RL-XII_Belatacept_2015-07-15-D-173.pdf2026-08-26T07:56:54.351Z"2c736647b803ab5ced175eaffde72097"117108STANDARD2206203922062039Normalkb-subset/2016-01-07_AM-RL-XII_Belatacept_2015-07-15-D-173_TrG.pdf2026-08-26T07:56:54.357Z"039a8e888bae84f4a5e34bf73fdfcb14"149316STANDARD2206203922062039Normalkb-subset/2016-01-07_AM-RL-XII_Nivolumab_2015-07-15-D-176.pdf2026-08-26T07:56:54.365Z"c0b4453134f37c0d5b9f4ca0762c6e05"110239STANDARD2206203922062039Normalkb-subset/2016-01-07_AM-RL-XII_Nivolumab_2015-07-15-D-176_TrG.pdf2026-08-26T07:56:54.368Z"0ace237452edc9138545dfd38ce56f6b"177450STANDARD2206203922062039Normalkb-subset/2016-01-12_Wortprotokoll_Pertuzumab-nAWG_2015-09-01-D-177.pdf2026-08-26T07:56:54.370Z"67fe275819548bdc529e6679bacca4b7"233576STANDARD2206203922062039Normalkb-subset/2016-01-21_AM-RL-XII_Edoxaban_2015-08-01-D-174.pdf2026-08-26T07:56:54.371Z"fd0218bce9fc4303ebac66773e21785d"121626STANDARD2206203922062039Normalkb-subset/2016-01-21_AM-RL-XII_Edoxaban_2015-08-01-D-174_TrG.pdf2026-08-26T07:56:54.380Z"dbf964cdc71da9f37f3ee9834fd795d1"208433STANDARD2206203922062039Normalkb-subset/2016-01-21_AM-RL-XII_Ivermectin_2015-06-01-D-170-Therapiekosten_BAnz.pdf2026-08-26T07:56:54.395Z"d10035eb1b7568888dfd5387bafedd62"581091STANDARD2206203922062039Normalkb-subset/2016-01-26_Wortprotokoll_end_Evolocumab.pdf2026-08-26T07:56:54.396Z"15ed066a6903b748447338bbba434123"388612STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Gaxilose_2015-08-15-D-185.pdf2026-08-26T07:56:54.400Z"c227008f8beeaec19efac1d21e5e303d"64346STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Gaxilose_2015-08-15-D-185_TrG.pdf2026-08-26T07:56:54.397Z"cb5e584cedcc4694f5ce1ed05878310c"82367STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Insulin-degludec-Liraglutid_2015-08-15-D-179.pdf2026-08-26T07:56:54.416Z"9f2f366d6ee7dde1e7c58a5f3276a320"69308STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Insulin-degludec-Liraglutid_2015-08-15-D-179_TrG.pdf2026-08-26T07:56:54.419Z"8b02844bd29c6077dfcfb62c45efa252"128754STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Netupitant_Palonosetron_2015-08-15-D-172.pdf2026-08-26T07:56:54.431Z"d05e4378aaa59fddfd1d6e6f8cda740c"88539STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Netupitant_Palonosetron_2015-08-15-D-172_TrG.pdf2026-08-26T07:56:54.441Z"b55332b7103073572f3185a53a5d2a6f"177676STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Nivolumab_2015-07-15-D-184.pdf2026-08-26T07:56:54.439Z"df5ecc299fc939b46a0ff212bc92f455"94904STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Nivolumab_2015-07-15-D-184_TrG.pdf2026-08-26T07:56:54.435Z"8188e269e6510f1487331aa11f0c2e11"157484STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Pembrolizumab_2015-08-15-D-186.pdf2026-08-26T07:56:54.452Z"e3bc852fe56a8867f9e0ea1b00606453"179405STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Pembrolizumab_2015-08-15-D-186_TrG.pdf2026-08-26T07:56:54.461Z"a13bd1c104bb2efedae793ff33f572b4"223473STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Tiotropium_Olodaterol_2015-08-15-D-175.pdf2026-08-26T07:56:54.463Z"37032ca9921ea6b3250199c19ca03afe"173596STANDARD2206203922062039Normalkb-subset/2016-02-04_AM-RL-XII_Tiotropium_Olodaterol_2015-08-15-D-175_TrG.pdf2026-08-26T07:56:54.466Z"da63fcd543ad808d27a39308ac60429a"164270STANDARD2206203922062039Normalkb-subset/2016-02-08_Wortprotokoll_Trametinib_Dabrafenib-nAWG.pdf2026-08-26T07:56:54.466Z"7f74a43e3d635cdab5284c02999ca1a7"102692STANDARD2206203922062039Normalkb-subset/2016-02-08_Wortprotokoll_Trametinib_Dabrafenib-nAWG_end.pdf2026-08-26T07:56:54.482Z"2e1e66b0cb49fefa00436feb9eaa12bb"102693STANDARD2206203922062039Normalkb-subset/2016-02-08_Wortprotokoll_end_Panobinostat.pdf2026-08-26T07:56:54.482Z"87b8881fa5a7ac5a56ba37a4319e0729"136612STANDARD2206203922062039Normalkb-subset/2016-02-08_Wortprotokoll_end_Pomalidomid.pdf2026-08-26T07:56:54.493Z"064a38870e73fd76d3dde53d28f31acd"162106STANDARD2206203922062039Normalkb-subset/2016-02-08_Wortprotokoll_end_Regorafenib.pdf2026-08-26T07:56:54.497Z"7a799ac7ae779f591dd7426e5f343638"122424STANDARD2206203922062039Normalkb-subset/2016-02-09_Wortprotokoll_12-02-2016_Sebelipase_alfa.pdf2026-08-26T07:56:54.512Z"72e9451781d932279ab72c1eec5a61ef"111426STANDARD2206203922062039Normalkb-subset/2016-02-09_Wortprotokoll_end_Idebenon.pdf2026-08-26T07:56:54.517Z"8e08abd8a6a386921c5b35710e6d8154"156571STANDARD2206203922062039Normalkb-subset/2016-02-18_AM-TL-XII_Pertuzumab-nAWG_2015-09-01-D-177.pdf2026-08-26T07:56:54.513Z"548b1d83ad2607a79e9502198625293f"107368STANDARD2206203922062039Normalkb-subset/2016-02-18_AM-TL-XII_Pertuzumab-nAWG_2015-09-01-D-177_TrG.pdf2026-08-26T07:56:54.522Z"573dc0e62466eba43e73191a0e826cfa"183429STANDARD2206203922062039Normalkb-subset/2016-02-23_Wortprotokoll_20_end_Aclidiniumbromid.pdf2026-08-26T07:56:54.530Z"60cb420171c397f660007369d5421f42"70940STANDARD2206203922062039Normalkb-subset/2016-03-09_AM-RL-XII_Evolocumab_2015-09-15-D-181.pdf2026-08-26T07:56:54.533Z"c10225b2fbdc940faf46836fa72a930e"85524STANDARD2206203922062039Normalkb-subset/2016-03-09_AM-RL-XII_Evolocumab_2015-09-15-D-181_TrG.pdf2026-08-26T07:56:54.537Z"05baa8b94c10ecf298aab942d7d11323"187683STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Asfotase-alfa_D-188.pdf2026-08-26T07:56:54.547Z"54848f6c829c6f23610acd1d8d7b4b7d"142909STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Asfotase-alfa_D-188_EN.pdf2026-08-26T07:56:54.550Z"fb42bb35984a634cc25ebc10c6557285"1325105STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Asfotase-alfa_D-188_TrG.pdf2026-08-26T07:56:54.555Z"32df69c1d7ffee641f7c38b9154b475d"210100STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Asfotase-alfa_D-188_TrG_EN.pdf2026-08-26T07:56:54.562Z"a9ba5c36e1d6735c5327e9b0f34c0c86"801883STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Dabrafenib-neues_20AWG_2015-10-01-D-182.pdf2026-08-26T07:56:54.562Z"b3647c2e6bf98079436ac99e2d4af621"129490STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Dabrafenib-neues_20AWG_2015-10-01-D-182_TrG.pdf2026-08-26T07:56:54.570Z"5dc0b5eb825802c49053bd81d9514fa6"189814STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Idebenon_D-191.pdf2026-08-26T07:56:54.576Z"cac6d01b2b2102bf5be3f587e79c5697"86428STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Idebenon_D-191_EN.pdf2026-08-26T07:56:54.590Z"7543438031426befd8628851057d87a9"1238587STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Idebenon_D-191_TrG.pdf2026-08-26T07:56:54.593Z"e8e810bad6ebc2f60ce6624edc4b82b7"144364STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Idebenon_D-191_TrG_EN.pdf2026-08-26T07:56:54.597Z"85ffb72299cd7bd6415c85938603e754"812258STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Panobinostat_D-180.pdf2026-08-26T07:56:54.601Z"ed9f47198c6366ab12ba5ff0ab7ca9ad"98793STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Panobinostat_D-180_TrG.pdf2026-08-26T07:56:54.604Z"5003f848a56d85f8bc066b0706cdd626"115724STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Pomalidomid_D-193.pdf2026-08-26T07:56:54.612Z"34c15331573e1424d1ca1fcc7d49c4c2"130223STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Pomalidomid_D-193_TrG.pdf2026-08-26T07:56:54.629Z"d46cb5591dfecc4966b25b40398283c4"159056STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Regorafenib_2015-10-01-D-189.pdf2026-08-26T07:56:54.631Z"c377b61b9131ded849729776461b0f8f"150158STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Regorafenib_2015-10-01-D-189_TrG.pdf2026-08-26T07:56:54.628Z"451c3c53f2bddafa68c8128ccc247711"135601STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Sebelipase-alfa_D-187.pdf2026-08-26T07:56:54.632Z"26386604e4d3531d3a750aa8c6f117ed"133191STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Sebelipase-alfa_D-187_TrG.pdf2026-08-26T07:56:54.638Z"cd1d5b2fae28dbcf3e1297cfe482d7de"132032STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Trametinib_2015-10-01-D-183.pdf2026-08-26T07:56:54.645Z"bcaa7b439ef833984cbcc001370b3970"132717STANDARD2206203922062039Normalkb-subset/2016-03-17_AM-RL-XII_Trametinib_2015-10-01-D-183_TrG.pdf2026-08-26T07:56:54.662Z"8082fc4dc992c3f520ff205437fbbc3f"197107STANDARD2206203922062039Normalkb-subset/2016-03-22-Wortprotokoll-end_Isavuconazol.pdf2026-08-26T07:56:54.664Z"37b2666cf9823cee094acb4ac04826a5"227363STANDARD2206203922062039Normalkb-subset/2016-03-22_Wortprotokoll-end-Alirocumab.pdf2026-08-26T07:56:54.664Z"6bd7f2eb40b2fb0eb0d46dfea4890663"214342STANDARD2206203922062039Normalkb-subset/2016-04-07_AM-RL-XII_Aclidiniumbromid_2015-10-15-D-190.pdf2026-08-26T07:56:54.677Z"bf8a84361565115d4b42720caf0f2069"132431STANDARD2206203922062039Normalkb-subset/2016-04-07_AM-RL-XII_Aclidiniumbromid_2015-10-15-D-190_TrG.pdf2026-08-26T07:56:54.674Z"e4fd73c20b9ca9f402286e025ee64073"180122STANDARD2206203922062039Normalkb-subset/2016-04-11_Wortprotokoll_end_26-04-2016_Fingolimod.pdf2026-08-26T07:56:54.678Z"ec17071340b0daeb97894fbdd6ec8f8f"168805STANDARD2206203922062039Normalkb-subset/2016-04-11_Wortprotokoll_end_Aflibercept_nAWG.pdf2026-08-26T07:56:54.695Z"ab872851bfb27acb9e16e588e51e78e5"74556STANDARD2206203922062039Normalkb-subset/2016-04-21_AM-RL-XII_Idelalisib_2014-10-01-D-135_BAnz.pdf2026-08-26T07:56:54.696Z"7d01c1ea16f39077d643a2407ad2b1d1"585055STANDARD2206203922062039Normalkb-subset/2016-04-25_Wortprotokoll_Ivacaftor_D200.pdf2026-08-26T07:56:54.704Z"fca2427363e175a6f3088927b2dd00d4"77906STANDARD2206203922062039Normalkb-subset/2016-04-25_Wortprotokoll_Lumacaftor-Ivacaftor.pdf2026-08-26T07:56:54.704Z"d5c87d0811ca3a76f6df35359cf2dd2c"155263STANDARD2206203922062039Normalkb-subset/2016-04-25_Wortprotokoll_end_Blinatumomab.pdf2026-08-26T07:56:54.704Z"d8b2b33a892962800cdab9c5e7a81721"136882STANDARD2206203922062039Normalkb-subset/2016-04-25_Wortprotokoll_end_Carfilzomib.pdf2026-08-26T07:56:54.710Z"54c86e2e74b8f5c37add71f00a5b119a"186983STANDARD2206203922062039Normalkb-subset/2016-04-25_Wortprotokoll_end_Cobimetinib.pdf2026-08-26T07:56:54.721Z"6f1d5f26ceb4f93de3eda32d5370e405"125445STANDARD2206203922062039Normalkb-subset/2016-05-02_Wortprotokoll_end_25-04-2016_Secukinumab_nAWG.pdf2026-08-26T07:56:54.734Z"d9028897367b5d9e3a49ab985f6fdf41"74474STANDARD2206203922062039Normalkb-subset/2016-05-04_AM-RL-XII_Isavuconazol_2015-11-15_D-192.pdf2026-08-26T07:56:54.738Z"0aedce2235f70b48fce46867695b2008"128004STANDARD2206203922062039Normalkb-subset/2016-05-04_AM-RL-XII_Isavuconazol_2015-11-15_D-192_TrG.pdf2026-08-26T07:56:54.741Z"7de604c0d3062e47f316b6bdda3603d1"108511STANDARD2206203922062039Normalkb-subset/2016-05-04_A_3B-RL-XII_Alirocumab_2015-11-15-D-194.pdf2026-08-26T07:56:54.753Z"582e85d6877a12c550637de41865c46c"101669STANDARD2206203922062039Normalkb-subset/2016-05-04_A_3B-RL-XII_Alirocumab_2015-11-15-D-194_TrG.pdf2026-08-26T07:56:54.755Z"0690dbae995bb8f4b5de73e825fe8867"242950STANDARD2206203922062039Normalkb-subset/2016-05-09_Wortprotokoll_Crizotinib_D205.pdf2026-08-26T07:56:54.768Z"ad61d3a7c6aeef3c3e643d051fbc88e5"128708STANDARD2206203922062039Normalkb-subset/2016-05-09_Wortprotokoll_Efmoroctocog_D195.pdf2026-08-26T07:56:54.765Z"1b2e6f1038ff7736b5ade4d2112ba57a"96143STANDARD2206203922062039Normalkb-subset/2016-05-09_Wortprotokoll_Sacubitril-Valsartan.pdf2026-08-26T07:56:54.769Z"6ab192636f255e2466751d769fef8ad2"215114STANDARD2206203922062039Normalkb-subset/2016-05-09_Wortprotokoll_end_Elvitegravir.pdf2026-08-26T07:56:54.767Z"ba16c59c03e25958652dbddd810182ae"102011STANDARD2206203922062039Normalkb-subset/2016-05-09_Wortprotokoll_end_Rilpivirin.pdf2026-08-26T07:56:54.766Z"0bf81bccf0084e2a775b69a5895bac7c"72464STANDARD2206203922062039Normalkb-subset/2016-05-19_AM-RL-XII_Aflibercept-nAWG_D-197.pdf2026-08-26T07:56:54.772Z"722b55d22f19d0dcf90206865c4e3cae"63282STANDARD2206203922062039Normalkb-subset/2016-05-19_AM-RL-XII_Aflibercept-nAWG_D-197_TrG.pdf2026-08-26T07:56:54.787Z"dd158ab64330abf0d6a822c1b0529776"165907STANDARD2206203922062039Normalkb-subset/2016-05-19_AM-RL-XII_Fingolimod_nAWG_D-198.pdf2026-08-26T07:56:54.796Z"635030c2c8713194357d126a8e89b006"198563STANDARD2206203922062039Normalkb-subset/2016-05-19_AM-RL-XII_Fingolimod_nAWG_D-198_TrG.pdf2026-08-26T07:56:54.805Z"2d63ca53e95f3ee5185976c2daef8ad1"184998STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Blinatumomab_D-201.pdf2026-08-26T07:56:54.811Z"f547d90e105a219960f6223d477f9e31"116480STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Blinatumomab_D-201_TrG.pdf2026-08-26T07:56:54.822Z"836af899026f9e789063dca4b2779dd8"115715STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Carfilzomib.pdf2026-08-26T07:56:54.838Z"bae8870432747e36ef526a6628b79390"110158STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Carfilzomib_TrG.pdf2026-08-26T07:56:54.851Z"05d323c72bbba21fd9aede125defbfa9"131739STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Cobimetinib_D-196.pdf2026-08-26T07:56:54.852Z"adf3a7af8f028259a1cf412da3fa2a87"118666STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Cobimetinib_D-196_TrG.pdf2026-08-26T07:56:54.865Z"295d49a188f26f5e617c1647d5c061e8"154750STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Ivacaftor_nAWG_2015-12-15-D-200.pdf2026-08-26T07:56:54.851Z"76ed88f2efb33483f9e3caa4b57d1ddb"155217STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Ivacaftor_nAWG_2015-12-15-D-200_TrG.pdf2026-08-26T07:56:54.857Z"2b7857d381eefd23a92ac0d135864eba"124599STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Lmacaftor-Ivacaftor_D-204_TrG.pdf2026-08-26T07:56:54.860Z"a418ee957183f9ea8255ed5dddddd6c9"128922STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Lumacaftor-Ivacaftor_D-204.pdf2026-08-26T07:56:54.861Z"0cc14631aace3b41da26eb35863bebf1"173597STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Secukinumab-nAWG_D-202.pdf2026-08-26T07:56:54.865Z"421cdb0521814dff57b0df92f1caf82c"99221STANDARD2206203922062039Normalkb-subset/2016-06-02_AM-RL-XII_Secukinumab-nAWG_D-202_TrG.pdf2026-08-26T07:56:54.875Z"82adc51f314261d8c8ac0631a7f1fe45"144783STANDARD2206203922062039Normalkb-subset/2016-06-06_Wortprotokoll_end_Ibrutinib.pdf2026-08-26T07:56:54.880Z"efe8f7818c0d4f456f2921699fcb4a57"195129STANDARD2206203922062039Normalkb-subset/2016-06-06_Wortprotokoll_end_Mepolizumab.pdf2026-08-26T07:56:54.894Z"1b4e716718c45cda8e461de251ebbcb5"112664STANDARD2206203922062039Normalkb-subset/2016-06-06_Wortprotokoll_end_Umeclidinium.pdf2026-08-26T07:56:54.905Z"becd904cbc060db35fd89150768f0e5a"63679STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Dasabuvir_D-152_Aenderung_BAnz.pdf2026-08-26T07:56:54.921Z"a310db18bb36cc77d6bbfce795643ede"578173STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Efmoroctocog-alfa_D-195.pdf2026-08-26T07:56:54.922Z"fb86f6f93a906a206028ac13325a979f"70214STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Efmoroctocog-alfa_D-195_TrG.pdf2026-08-26T07:56:54.928Z"a558a23b0cd16282e152755a85245f80"136810STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Elvitagravir-Cobicistat-Emtricitabin-Tenofoviralafenamid_D-206.pdf2026-08-26T07:56:54.930Z"ac6e20e006e688838963a24733b15f4b"167352STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Elvitagravir-Cobicistat-Emtricitabin-Tenofoviralafenamid_D-206_TrG.pdf2026-08-26T07:56:54.935Z"23944fd29b5f37cf17c1fc911d566cde"229075STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Evolocumab_D-181_Aenderung_BAnz.pdf2026-08-26T07:56:54.941Z"b0af09f1cb2a72b2fadf86e9cd8d7910"781813STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Rilpivirin_nAWG_D-209.pdf2026-08-26T07:56:54.937Z"fc18fd39d17552d1dd0adcbab0819d1b"94716STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Rilpivirin_nAWG_D-209_TrG.pdf2026-08-26T07:56:54.936Z"77b82daad99577fa1269ba98eb51bf34"122123STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Sacubutril_Valsartan_D-207.pdf2026-08-26T07:56:54.939Z"a6623b01140f9164219efa6e0f2fc68a"128493STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-RL-XII_Sacubutril_Valsartan_D-207_TrG.pdf2026-08-26T07:56:54.950Z"997fd8641c68c707153ec3fe0d66c508"198969STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-Rl-XII_Crizotinib_nAWG_D-205.pdf2026-08-26T07:56:54.959Z"c13e3396a8b170b1a2f5f74b9afc30c5"148577STANDARD2206203922062039Normalkb-subset/2016-06-16_AM-Rl-XII_Crizotinib_nAWG_D-205_TrG.pdf2026-08-26T07:56:54.974Z"f69900fd4d6c346a964cdbb7240e8828"151548STANDARD2206203922062039Normalkb-subset/2016-06-20_Wortprotokoll_end_Afamelanotid.pdf2026-08-26T07:56:54.986Z"9996070ee710e398d5d42b5b4b0d3789"110801STANDARD2206203922062039Normalkb-subset/2016-06-20_Wortprotokoll_end_Vismodegib.pdf2026-08-26T07:56:55.008Z"b7905351e7baa81a3c0d7c947742849b"129608STANDARD2206203922062039Normalkb-subset/2016-06-27_Wortprotokoll_end_Brivaracetam.pdf2026-08-26T07:56:55.009Z"979f513c6be65c1d7c36b8ee15354533"195697STANDARD2206203922062039Normalkb-subset/2016-07-11_Wortprotokoll_Empagliflozin-Metformin_D-214.pdf2026-08-26T07:56:55.014Z"0a11b4fb1a42ef3488c4dbde8740cfd9"178260STANDARD2206203922062039Normalkb-subset/2016-07-11_Wortprotokoll_Empagliflozin-Metformin_D-215.pdf2026-08-26T07:56:55.023Z"c94ef2c1ebc08ee67f55aa1506f7dc1b"178260STANDARD2206203922062039Normalkb-subset/2016-07-11_Wortprotokoll_Ramucirumab-Lungenkarzinom_D-217.pdf2026-08-26T07:56:55.025Z"14aa262748bfd89901aa9e366289ac83"90631STANDARD2206203922062039Normalkb-subset/2016-07-11_Wortprotokoll_Ramucirumab_D-216.pdf2026-08-26T07:56:55.029Z"8b796ec1302d11bbc987331945198ced"112069STANDARD2206203922062039Normalkb-subset/2016-07-21_AM-RL-XII_Ibrutinib_D-212.pdf2026-08-26T07:56:55.035Z"2528f27fd464696e60fb921ed68f64a1"159675STANDARD2206203922062039Normalkb-subset/2016-07-21_AM-RL-XII_Ibrutinib_D-212_TrG.pdf2026-08-26T07:56:55.034Z"319d0e7c996190bbe83d34033fddad41"308277STANDARD2206203922062039Normalkb-subset/2016-07-21_AM-RL-XII_Mepolizumab_D-211.pdf2026-08-26T07:56:55.035Z"862c95db0bd168b0cbdb794e5161680a"101313STANDARD2206203922062039Normalkb-subset/2016-07-21_AM-RL-XII_Mepolizumab_D-211_TrG.pdf2026-08-26T07:56:55.038Z"eba5df90027a010b56aa58c56c12be20"214637STANDARD2206203922062039Normalkb-subset/2016-07-21_AM-RL-XII_Umeclidinium_D-210.pdf2026-08-26T07:56:55.045Z"0a8c86f6bf9c1c7f7642b8ced0950c24"90532STANDARD2206203922062039Normalkb-subset/2016-07-21_AM-RL-XII_Umeclidinium_D-210_TrG.pdf2026-08-26T07:56:55.050Z"d53cd54dc357a9186c8ae1957fbe403b"145645STANDARD2206203922062039Normalkb-subset/2016-07-26_Wortprotokoll_Osimertinib_D-219.pdf2026-08-26T07:56:55.099Z"94950b2c5d6ade0eb1b5e05ce6cb53b9"137432STANDARD2206203922062039Normalkb-subset/2016-08-04_AM-RL-XII_Afamelanotid_D-218.pdf2026-08-26T07:56:55.105Z"38803a0489501f21548d711482c06e8a"267681STANDARD2206203922062039Normalkb-subset/2016-08-04_AM-RL-XII_Afamelanotid_D-218_TrG.pdf2026-08-26T07:56:55.108Z"cc22d7a54dec6d8e9e9d98ee5294ca07"221767STANDARD2206203922062039Normalkb-subset/2016-08-04_AM-RL-XII_Brivaracetam_D-208.pdf2026-08-26T07:56:55.112Z"9d9d74139a8501fc9aca606990617756"66080STANDARD2206203922062039Normalkb-subset/2016-08-04_AM-RL-XII_Brivaracetam_D-208_TrG.pdf2026-08-26T07:56:55.111Z"ee057a8cedeab4a402d05826d0778297"212775STANDARD2206203922062039Normalkb-subset/2016-08-04_AM-RL-XII_Vismodegib_D-213.pdf2026-08-26T07:56:55.118Z"231777d7dbb713e64f50abbf0261dd81"311829STANDARD2206203922062039Normalkb-subset/2016-08-04_AM-RL-XII_Vismodegib_D-213_TrG.pdf2026-08-26T07:56:55.112Z"d686c62d2713c023bc892dfa9a6f11ba"277463STANDARD2206203922062039Normalkb-subset/2016-08-08_Wortprotokoll_Idelalisib_D-222.pdf2026-08-26T07:56:55.117Z"4e914bb5f8a63e8067a3921301fc3715"101833STANDARD2206203922062039Normalkb-subset/2016-08-08_Wortprotokoll_Necitumumab_D-221.pdf2026-08-26T07:56:55.113Z"da19a9073164b0a67925c2f0278aedac"82656STANDARD2206203922062039Normalkb-subset/2016-08-08_Wortprotokoll_Ticagrelor-nAWG_D-220.pdf2026-08-26T07:56:55.115Z"a43ac67a8684ff97b8047969ccd38981"112953STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Empagliflozin_D-214.pdf2026-08-26T07:56:55.114Z"5da168cd3bd5d3d68c80da4f845058e5"167044STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Empagliflozin_D-214_TrG.pdf2026-08-26T07:56:55.119Z"d58fd50d4e08a43f31d51f7a3e478f5f"320751STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Empagliflozin_Metformin_D-215.pdf2026-08-26T07:56:55.176Z"b1a018aa15f54b2ab2e94c7af478b0d3"110726STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Empagliflozin_Metformin_D-215_TrG.pdf2026-08-26T07:56:55.176Z"02037c18e56c396b86afa5957871e241"222117STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Ramucirumab_D-216.pdf2026-08-26T07:56:55.179Z"8cc894abbacf9fc128c3a6cfc49aa530"321757STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Ramucirumab_D-216_TrG.pdf2026-08-26T07:56:55.180Z"0cb1d954974ffd0b15de6be7fbe08ba9"160715STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Ramucirumab_nAWG.pdf2026-08-26T07:56:55.188Z"a9600c330e4034057bfe994a42438efa"115259STANDARD2206203922062039Normalkb-subset/2016-09-01_AM-RL-XII_Ramucirumab_nAWG_TrG.pdf2026-08-26T07:56:55.186Z"99d02f17225e38d90cc4dc94bc1ad78b"158135STANDARD2206203922062039Normalkb-subset/2016-09-02_Wortprotokoll_end_Asfotase_alfa.pdf2026-08-26T07:56:55.182Z"0c054431f1dac9d485097c118f4ac8a4"122480STANDARD2206203922062039Normalkb-subset/2016-09-05_Wortprotokoll_Afatinib_D-226.pdf2026-08-26T07:56:55.186Z"49454f1ff1366425b47d7ec23ee27ca0"122060STANDARD2206203922062039Normalkb-subset/2016-09-05_Wortprotokoll_Nivolumab-Nierenzellkarzinom_D-230.pdf2026-08-26T07:56:55.184Z"eaaff43110161a8abe846ef8f7295b62"112503STANDARD2206203922062039Normalkb-subset/2016-09-05_Wortprotokoll_Nivolumab_28NSCLC_29_D-231.pdf2026-08-26T07:56:55.190Z"2ec53aee2a6d392a75fd84b1c539c930"110837STANDARD2206203922062039Normalkb-subset/2016-09-05_Wortprotokoll_Ospemifen_D-223.pdf2026-08-26T07:56:55.191Z"fdb0476ec6b91c82c374a4473c025502"144826STANDARD2206203922062039Normalkb-subset/2016-09-05_Wortprotokoll_Ramucirumab_D-224.pdf2026-08-26T07:56:55.192Z"e4995f28edae79d18bac0e1e428b533a"84316STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Idelalisib_D-222.pdf2026-08-26T07:56:55.252Z"e353657be6782e177644c9494940e89a"130076STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Idelalisib_D-222_TrG.pdf2026-08-26T07:56:55.267Z"415f3b193f52cb92de015b28ffbd1c9f"227846STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Necitumumab_D-221.pdf2026-08-26T07:56:55.271Z"1abb9764997bbfc54b778a35db1e1b88"271927STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Necitumumab_D-221_TrG.pdf2026-08-26T07:56:55.272Z"a536d94363fcf4d0687b7eaf9962a600"389716STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Osimertinib_D-219.pdf2026-08-26T07:56:55.271Z"a899635d6588fef64f05689c16fcaeb7"285359STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Osimertinib_D-219_TrG.pdf2026-08-26T07:56:55.279Z"8829323749aa4ef9d31c76a451843678"333779STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Ticagrelor_nAWG_D-220.pdf2026-08-26T07:56:55.275Z"f32d34394636c50fde9d973764902daf"70508STANDARD2206203922062039Normalkb-subset/2016-09-15_AM-RL-XII_Ticagrelor_nAWG_D-220_TrG.pdf2026-08-26T07:56:55.273Z"6ecc64039f829981cfe4c491b490947f"132450STANDARD2206203922062039Normalkb-subset/2016-09-20_Wortprotokoll_Emtricitabin-Tenofoviralafenamid_D-228.pdf2026-08-26T07:56:55.275Z"63ce56441dd498b68fe90313dfb55993"125815STANDARD2206203922062039Normalkb-subset/2016-10-10_Wortprotokoll_Ataluren_D-239.pdf2026-08-26T07:56:55.277Z"132fd9009828f1ae7bbb3dbf9c144318"107338STANDARD2206203922062039Normalkb-subset/2016-10-10_Wortprotokoll_Daratumumab_D-238.pdf2026-08-26T07:56:55.281Z"b1c04ef8db39b075012a2453ea4e826c"95830STANDARD2206203922062039Normalkb-subset/2016-10-10_Wortprotokoll_Elotuzumab_D-232.pdf2026-08-26T07:56:55.280Z"347e173ef7969428b9369c4fd6a3cad8"99440STANDARD2206203922062039Normalkb-subset/2016-10-10_Wortprotokoll_Eribulin_D-234.pdf2026-08-26T07:56:55.338Z"a64016c6c1417a245fe958aa728887cb"220103STANDARD2206203922062039Normalkb-subset/2016-10-10_Wortprotokoll_Migalastat_D-225.pdf2026-08-26T07:56:55.346Z"e651bb7900cdfcf83f419d6197550a36"136307STANDARD2206203922062039Normalkb-subset/2016-10-11_Wortprotokoll_Albutrepenonacog_alfa_D-227.pdf2026-08-26T07:56:55.347Z"6c44e9ddf56c08e1596386cfb0741033"102337STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Afatinib_D-226.pdf2026-08-26T07:56:55.350Z"506d9b67cac0e93e0a36c4c7266e5a4c"249922STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Afatinib_D-226_TrG.pdf2026-08-26T07:56:55.348Z"9de023762ee2e123eb2969e5f56b735a"259929STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Nivolumab-nAWG-NSCLC_D-231.pdf2026-08-26T07:56:55.348Z"3f08e592d34a10a7095bc48262ba6e02"148079STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Nivolumab-nAWG-NSCLC_D-231_TrG.pdf2026-08-26T07:56:55.349Z"339192d0986f36f22800655d7c6e070b"314264STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Nivolumab_Nierenzellkarzinom_D-230.pdf2026-08-26T07:56:55.354Z"7bb065bd2dbfedae631a6300a7d6c6fd"107419STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Nivolumab_Nierenzellkarzinom_D-230_TrG.pdf2026-08-26T07:56:55.353Z"58c1d9ff913bb0da37149d3d88119a02"185493STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Ospemifen_D-223.pdf2026-08-26T07:56:55.353Z"061e33b7c902a6725016a65ebbdc2a6a"65553STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Ospemifen_D-223_TrG.pdf2026-08-26T07:56:55.352Z"d98dc72f68fbdba4cc9aaa46210504e6"121838STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Ramucirumab_Magenkarzinom_D-224.pdf2026-08-26T07:56:55.357Z"7d3bd7ea6450c55c4c8dabfafc244caa"180819STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Ramucirumab_Magenkarzinom_D-224_TrG.pdf2026-08-26T07:56:55.413Z"2104c859ac973ee4cee8009aedcf35f2"217473STANDARD2206203922062039Normalkb-subset/2016-10-20_AM-RL-XII_Umeclidinium_D-210_Therapiekosten_BAnz.pdf2026-08-26T07:56:55.414Z"21a76b8f3d105a6d10f731ac76050057"685851STANDARD2206203922062039Normalkb-subset/2016-10-24_Wortprotokoll_Eftrenonacog_alfa_D-233.pdf2026-08-26T07:56:55.412Z"ce2d7a3272a6b8178d92541dcf96c7be"106962STANDARD2206203922062039Normalkb-subset/2016-10-24_Wortprotokoll_Nivolumab-nAWG_D-241.pdf2026-08-26T07:56:55.417Z"e2ced0b4e3ef90943912c129ddb7ec77"115912STANDARD2206203922062039Normalkb-subset/2016-10-24_Wortprotokoll_Selexipag_D-236.pdf2026-08-26T07:56:55.421Z"2ce91552fc3de7ed641e5f9b0cb66187"167618STANDARD2206203922062039Normalkb-subset/2016-10-24_Wortprotokoll_Talimogen-laherparepvec.pdf2026-08-26T07:56:55.417Z"2d1cf6fb193f936fe8056a1d83a31273"102899STANDARD2206203922062039Normalkb-subset/2016-11-03_AM-RL-XII_Emtricitabin_Tenofoviralafenamid_D-228.pdf2026-08-26T07:56:55.416Z"73da9fdab5975ad1c9f298c793a2a213"378184STANDARD2206203922062039Normalkb-subset/2016-11-03_AM-RL-XII_Emtricitabin_Tenofoviralafenamid_D-228_TrG.pdf2026-08-26T07:56:55.423Z"3eeaceec87a6fb3a2bf37b7ca3e824a5"393486STANDARD2206203922062039Normalkb-subset/2016-11-07_Wortprotokoll_Crizotinib_D-240.pdf2026-08-26T07:56:55.436Z"a903e06049e37ff3c532eb5904b8c5a3"114255STANDARD2206203922062039Normalkb-subset/2016-11-07_Wortprotokoll_Ibrutinib_D-249.pdf2026-08-26T07:56:55.426Z"632b05b81fb3aa9a706f4b74e4e67169"139143STANDARD2206203922062039Normalkb-subset/2016-11-07_Wortprotokoll_Saxagliptin_Metformin_D-243.pdf2026-08-26T07:56:55.429Z"84bbd0b628aa4b11d98455fb553b3c76"115507STANDARD2206203922062039Normalkb-subset/2016-11-07_Wortprotokoll_Saxagliptin_Metformin_D-244.pdf2026-08-26T07:56:55.428Z"62c17b12ade2ceb0ec7dbfcef051b82e"115520STANDARD2206203922062039Normalkb-subset/2016-11-07_Wortprotokoll_Sitagliptin_Metformin_D-245.pdf2026-08-26T07:56:55.488Z"cb05211b2aba33ed1ecdefa572f59e63"168482STANDARD2206203922062039Normalkb-subset/2016-11-07_Wortprotokoll_Sitagliptin_Metformin_D-246.pdf2026-08-26T07:56:55.487Z"6e6185a41b3c883f0994c110e8b379a1"168468STANDARD2206203922062039Normalkb-subset/2016-11-17_Wortprotokoll_Obinutuzumab_D-229_20.doc.pdf2026-08-26T07:56:55.488Z"f3c4f7147d313ceb237aef78599e65d5"107394STANDARD2206203922062039Normalkb-subset/2016-11-22_Wortprotokoll_Emtricitabin_Tenofoviralafenamid_Rilpivirin_D-248.pdf2026-08-26T07:56:55.488Z"ed1c6099b42e4187f8b6c97c84dcd792"47142STANDARD2206203922062039Normalkb-subset/2016-11-22_Wortprotokoll_Sofosbuvir_Velpatasvir_D-247.pdf2026-08-26T07:56:55.493Z"bdc2980aa62b21aa5307e3b1f1855ae7"113727STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Albutrepenonacog_D-227.pdf2026-08-26T07:56:55.496Z"351195464470cd1e0e41a5781b63966f"144387STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Albutrepenonacog_D-227_TrG.pdf2026-08-26T07:56:55.491Z"7e7d274318a53c0933e8ac9a3242969b"374815STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Ataluren_D-239.pdf2026-08-26T07:56:55.494Z"66f62c55492f8eab4b00f9b3c3673095"175853STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Ataluren_D-239_EN.pdf2026-08-26T07:56:55.495Z"2803dae0aac6d1312f93937eae29fe7a"1439462STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Ataluren_D-239_TrG.pdf2026-08-26T07:56:55.500Z"0cbce4e768aa566fc3ec254c29212484"145954STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Ataluren_D-239_TrG_EN.pdf2026-08-26T07:56:55.502Z"5a70edaa0e8fe02f72c815693eef6b68"826463STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Daratumumab_D-238.pdf2026-08-26T07:56:55.502Z"5fe5fbf1d196cb12b7dc7d0baa700f47"98596STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Daratumumab_D-238_TrG.pdf2026-08-26T07:56:55.555Z"eda611c7ac563ba97a066871bbff5d75"149330STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Elotuzumab_D-232.pdf2026-08-26T07:56:55.555Z"f79f4431300743deda2429cad474b2f2"161255STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Elotuzumab_D-232_TrG.pdf2026-08-26T07:56:55.556Z"d3717748cd67ba5e7d9a16cf3eb215d4"199336STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Eribulin_nAWG_D-234.pdf2026-08-26T07:56:55.561Z"fa22239c0e129bd795c5f35ced6afe87"111762STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Eribulin_nAWG_D-234_TrG.pdf2026-08-26T07:56:55.564Z"42ee162d332fb792f51cef370f9324c0"196082STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Migalastat_D-255.pdf2026-08-26T07:56:55.564Z"c6655c93a857cc88aa20944609294478"122558STANDARD2206203922062039Normalkb-subset/2016-12-01_AM-RL-XII_Migalastat_D-255_TrG.pdf2026-08-26T07:56:55.566Z"c205e7f047980d6f023eb2fa2aa686f7"145844STANDARD2206203922062039Normalkb-subset/2016-12-05_Wortprotokoll_Pitolisant_D-250.pdf2026-08-26T07:56:55.563Z"3c7deaceb50c73e1e63dc34754c6ca48"138910STANDARD2206203922062039Normalkb-subset/2016-12-05_Wortprotokoll_Tasimelteon_D-242.pdf2026-08-26T07:56:55.562Z"31229c554b9152561d0b15a885b93f01"125454STANDARD2206203922062039Normalkb-subset/2016-12-06_Wortprotokoll_Brentuximab_Vedotin_D-253.pdf2026-08-26T07:56:55.566Z"9e1354aa25a0765b34207b8af70dfe98"101141STANDARD2206203922062039Normalkb-subset/2016-12-06_Wortprotokoll_Carfilzomib-nAWG_D-255_.pdf2026-08-26T07:56:55.567Z"3283d36ca21bdb52162d9c2194b8928a"97628STANDARD2206203922062039Normalkb-subset/2016-12-12_AM-RL-XII_Nivolumab_nAWG_D-241.pdf2026-08-26T07:56:55.569Z"18aaf914fc924e38950951e5cc3a6978"92808STANDARD2206203922062039Normalkb-subset/2016-12-12_AM-RL-XII_Nivolumab_nAWG_D-241_TrG.pdf2026-08-26T07:56:55.620Z"58750a200122769b066a9b20fa6e113b"138610STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Crizotinib_D-240.pdf2026-08-26T07:56:55.620Z"a277abda069f15a97a42577c720c99de"156939STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Crizotinib_D-240_TrG.pdf2026-08-26T07:56:55.625Z"8f1602a232837e5997ad285e95dc98a5"186259STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Eftrenonacog-alfa_D-233.pdf2026-08-26T07:56:55.625Z"304a42c8bc91a59d6595c920313a830f"139788STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Eftrenonacog-alfa_D-233_TrG.pdf2026-08-26T07:56:55.627Z"3c2fc39a9f04fc8d2ba34ef1dcb0d051"145122STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Ibrutinib_nAWG_D-249.pdf2026-08-26T07:56:55.633Z"5dfa660610a18cca741e17ff70b1e1b8"82998STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Ibrutinib_nAWG_D-249_TrG.pdf2026-08-26T07:56:55.633Z"0ed5155c57ec04483f5a0004f3085d58"186634STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Obinutuzumab_D-229.pdf2026-08-26T07:56:55.637Z"282d9c34cf4376aab0925747678f08dd"181028STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Obinutuzumab_D-229_TrG.pdf2026-08-26T07:56:55.636Z"31ea4489cbcd8da087f63177cacf0fee"156273STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Saxagliptin-Metformin_D-244.pdf2026-08-26T07:56:55.635Z"098c08c6d21181c6dd0e1a8426a95ed7"61794STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Saxagliptin-Metformin_D-244_TrG.pdf2026-08-26T07:56:55.636Z"5f525787c5d22191bd97970a0c945f5e"192191STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Saxagliptin_D-243.pdf2026-08-26T07:56:55.645Z"84786f13df8fd300acf00e5b6a871cbb"183106STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Saxagliptin_D-243_TrG.pdf2026-08-26T07:56:55.686Z"3d5d0db6ee0d159a204b1dffccce06b2"248150STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Selexipag_D-236.pdf2026-08-26T07:56:55.692Z"0e73494a07db924fe5db226587bb9c7d"70581STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Selexipag_D-236_TrG.pdf2026-08-26T07:56:55.699Z"d38beb84407acf38562532fea9f61bd0"226034STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Sitagliptin_D-245.pdf2026-08-26T07:56:55.698Z"fee332971814d839d76e10ef31171f7f"209293STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Sitagliptin_D-245_TrG.pdf2026-08-26T07:56:55.698Z"fc1534c9f086106779857f4a65c53100"299846STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Sitagliptin_Metformin_D-246.pdf2026-08-26T07:56:55.697Z"605dc256b4755695c6c8e527c314a825"91685STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Sitagliptin_Metformin_D-246_TrG.pdf2026-08-26T07:56:55.701Z"52bd4fd7341ea25eb420a7d6ee9bb61c"228359STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Talimogen-laherparepvec_D-237.pdf2026-08-26T07:56:55.705Z"5497c385490f5265a90fd754f28af7b1"94118STANDARD2206203922062039Normalkb-subset/2016-12-15_AM-RL-XII_Talimogen-laherparepvec_D-237_TrG.pdf2026-08-26T07:56:55.701Z"bc81fd7928c6e63b9820c09fa99d88d2"162735STANDARD2206203922062039Normalkb-subset/2016-12-20_Wortprotokoll_Pembrolizumab_nAWG-D-251.pdf2026-08-26T07:56:55.706Z"a388d7fb342bb6254ce655a19ae5df8f"124330STANDARD2206203922062039Normalkb-subset/2016-12-20_Wortprotokoll_Trifluridin-Tipiracil_D-252.pdf2026-08-26T07:56:55.711Z"3cb9005f35dd75238d39612f64a56e5a"207686STANDARD2206203922062039Normalkb-subset/2016_12_05_Wortprotokoll_Teduglutid_D-254.pdf2026-08-26T07:56:55.713Z"750e15c3f363aac4c033db15529c5a1e"96821STANDARD2206203922062039Normalkb-subset/2017-01-05_AM-RL-XII_Emtricitabin-Rilpivirin-TAF_D-248.pdf2026-08-26T07:56:55.764Z"ed3a867cd95fa6f98d8fdcb4fc55637a"100630STANDARD2206203922062039Normalkb-subset/2017-01-05_AM-RL-XII_Emtricitabin-Rilpivirin-TAF_D-248_TrG.pdf2026-08-26T07:56:55.760Z"db93fd8a1268a253149732d7897f0af5"168717STANDARD2206203922062039Normalkb-subset/2017-01-05_AM-RL-XII_Sofosbuvir-Velpatasvir_2016-07-15-D-247.pdf2026-08-26T07:56:55.765Z"85db87793d904afea0575a8f68a92c6c"151308STANDARD2206203922062039Normalkb-subset/2017-01-05_AM-RL-XII_Sofosbuvir-Velpatasvir_2016-07-15-D-247_TrG.pdf2026-08-26T07:56:55.761Z"efe643f2afbedd426eb9b422b35967c6"233941STANDARD2206203922062039Normalkb-subset/2017-01-15_Wortprotokoll_Ixazomib_D-272.pdf2026-08-26T07:56:55.767Z"b44b125bb91ae8afdde57d65d99e75be"166067STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Brentuximab-Vedotin_D-253.pdf2026-08-26T07:56:55.764Z"6ab6887e46d261a86b12d1bd2a36a27d"170613STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Brentuximab-Vedotin_D-253_TrG.pdf2026-08-26T07:56:55.773Z"295f3f090645aa84def497c15d643c67"175958STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Carfilzomib_nAWG-Kombi-Dexamethason_D-255.pdf2026-08-26T07:56:55.772Z"59a483e3526965c2eab823acb0dbadde"159498STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Carfilzomib_nAWG-Kombi-Dexamethason_D-255_TrG.pdf2026-08-26T07:56:55.780Z"bde57f7e4c11d28eb2f4a0bc62c8c0a3"147827STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Pitolisant_D-250.pdf2026-08-26T07:56:55.777Z"cde31644ec291af2cb84029b82b96173"149695STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Pitolisant_D-250_TrG.pdf2026-08-26T07:56:55.791Z"e174466b8fb3ca63b41a4463ed096f06"119357STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Tasimelteon_D-242.pdf2026-08-26T07:56:55.788Z"bef88bd2798f6ae9b4a23b640f481ddd"105800STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Tasimelteon_D-242_TrG.pdf2026-08-26T07:56:55.835Z"8380fa1518d0194e43e707891a7c59ad"134367STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Teduglutid_D-254.pdf2026-08-26T07:56:55.834Z"78d1ff2e418b245dc03aa1790c23b748"98164STANDARD2206203922062039Normalkb-subset/2017-01-19_AM-RL-XII_Teduglutid_D-254_TrG.pdf2026-08-26T07:56:55.837Z"3d8c24d33dfbc6a5c93264484e7e73e0"116715STANDARD2206203922062039Normalkb-subset/2017-02-02_AM-RL-XII_Pembrolizumab_D-251.pdf2026-08-26T07:56:55.841Z"0f0b0588ce4dcae2e47097311356e6e0"198659STANDARD2206203922062039Normalkb-subset/2017-02-02_AM-RL-XII_Pembrolizumab_D-251_TrG.pdf2026-08-26T07:56:55.841Z"b581989527f1012870484ef51a89ca85"220334STANDARD2206203922062039Normalkb-subset/2017-02-02_AM-RL-XII_Trifluridin-Tipiracil_D-252.pdf2026-08-26T07:56:55.846Z"e3b4d936a0a94e7641c9555fe8124d10"331257STANDARD2206203922062039Normalkb-subset/2017-02-02_AM-RL-XII_Trifluridin-Tipiracil_D-252_TrG.pdf2026-08-26T07:56:55.845Z"c7bdfaf3ae815deab691fe5d1463fd5b"473143STANDARD2206203922062039Normalkb-subset/2017-02-06_Wortprotokoll_Ceritinib_D-259.pdf2026-08-26T07:56:55.845Z"9ddaa0154f9c41310c533e042390fdf9"138728STANDARD2206203922062039Normalkb-subset/2017-02-21_Wortprotokoll_Macitentan_D-260pdf.pdf2026-08-26T07:56:55.845Z"d4fc50bd7a1a39fb1152127d55248da1"177468STANDARD2206203922062039Normalkb-subset/2017-03-07_Wortprotokoll_Cabozantinib_D-263.pdf2026-08-26T07:56:55.852Z"3964153ba54efb36e6df04270cc83b59"139431STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Ceritinib_D-259.pdf2026-08-26T07:56:55.854Z"2f7e4552d5b08244dec587d8d878fd43"144551STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Ceritinib_D-259_TrG.pdf2026-08-26T07:56:55.858Z"4730559091c74700a82badea9c9aed1a"193146STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Crizotinib_D-261.pdf2026-08-26T07:56:55.902Z"f0b263f9735eff5071db96251f0452f9"89037STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Crizotinib_D-261_TrG.pdf2026-08-26T07:56:55.911Z"ebc7c4d5db3db50abb6379a92ecdde35"188139STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Ibrutinib_nAWG-Laeukemie-D-262.pdf2026-08-26T07:56:55.912Z"bb67d17bbae1f70f12edc307867cbacc"140062STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Ibrutinib_nAWG-Laeukemie-D-262_TrG.pdf2026-08-26T07:56:55.913Z"ba64156e95d30b1052916722d335b3f6"186794STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Idelalisib_nAWG_Erstlinientherapie-Rituximab_D-256.pdf2026-08-26T07:56:55.914Z"c742daed80d0365350bf695c94ed9873"73156STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Idelalisib_nAWG_Erstlinientherapie-Rituximab_D-256_TrG.pdf2026-08-26T07:56:55.915Z"8502333c8a84bc3bb8992b214a3b994e"155795STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Idelalisib_nAWG_Kombination-Ofatumumab_D-256.pdf2026-08-26T07:56:55.922Z"1c1d8d03a62c2ea6563a4370223ca20a"95339STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Idelalisib_nAWG_Kombination-Ofatumumab_D-256_TrG.pdf2026-08-26T07:56:55.926Z"e2b49caf4943d6253bbb9aa67324d32a"194655STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Lenvatinib_D-257.pdf2026-08-26T07:56:55.927Z"fecccbf949288e16659b6c94debfc547"111981STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Lenvatinib_D-257_TrG.pdf2026-08-26T07:56:55.926Z"fd00193c40b09db614b0c8dd57a4a947"179353STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Opicapon_D-258.pdf2026-08-26T07:56:55.931Z"553aee21ce55b2597859f632e10ff966"116496STANDARD2206203922062039Normalkb-subset/2017-03-16_AM-RL-XII_Opicapon_D-258_TrG.pdf2026-08-26T07:56:55.929Z"c0759e5d24e4d4d269994a4b8ed1ca8b"158445STANDARD2206203922062039Normalkb-subset/2017-04-06_AM-RL-XII_Macitentan_D-260.pdf2026-08-26T07:56:55.976Z"2fddeda8a1b619584b52f64da0435b5d"68019STANDARD2206203922062039Normalkb-subset/2017-04-06_AM-RL-XII_Macitentan_D-260_TrG.pdf2026-08-26T07:56:55.977Z"b844978b524df33bd02f63714b6bf3a3"241871STANDARD2206203922062039Normalkb-subset/2017-04-20_AM-RL-XII_Cabozantinib-D-263-TrG.pdf2026-08-26T07:56:55.981Z"caae6ede1ca18ffc30a8e525eb7d6058"196738STANDARD2206203922062039Normalkb-subset/2017-04-20_AM-RL-XII_Cabozantinib-D-263.pdf2026-08-26T07:56:55.982Z"67575420d24a5dd54357257663332248"121767STANDARD2206203922062039Normalkb-subset/2017-05-09_Wortprotokoll_Nivolumab_nAWG_D-267.pdf2026-08-26T07:56:55.986Z"0ebcaf467bf23a4e535d48ab4efcb2a3"171102STANDARD2206203922062039Normalkb-subset/2017-05-09_Wortprotokoll_Venetoclax_D-266.pdf2026-08-26T07:56:55.989Z"60984a0178698ccc572a09c3497a7fc8"176488STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Olaratumab_D-265-TrG.pdf2026-08-26T07:56:55.994Z"e82d433e6225d585fa238d88a4a75ae2"159843STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Olaratumab_D-265.pdf2026-08-26T07:56:55.995Z"9004b9799e665ebbe6126b49d2896da7"150671STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Olaratumab_D-265_EN.pdf2026-08-26T07:56:55.999Z"364e8274110718ff022e478414f4970e"1316628STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Olaratumab_D-265_TrG_EN.pdf2026-08-26T07:56:55.997Z"b0b90724fc51c1ed902edaa10bac80c9"747448STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Palbociclib_D-264.pdf2026-08-26T07:56:56.001Z"1bd7895c565df80d99620849d2886640"175424STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Palbociclib_D-264_EN.pdf2026-08-26T07:56:56.002Z"436f3a1734d536739654fa89ef73a740"942544STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Palbociclib_D-264_TrG.pdf2026-08-26T07:56:56.042Z"d679b4503caa87f2e8a49a520d6daa90"370628STANDARD2206203922062039Normalkb-subset/2017-05-18_AM-RL-XII_Palbociclib_D-264_TrG_EN.pdf2026-08-26T07:56:56.044Z"0ee47619d58c769ff6eb6609b5e84ba2"1319262STANDARD2206203922062039Normalkb-subset/2017-05-22_Wortprotokoll_Obeticholsaeure_D-269.pdf2026-08-26T07:56:56.050Z"649272599b548ce5ce82f6e67833f982"121818STANDARD2206203922062039Normalkb-subset/2017-05-22_Wortprotokoll_Reslizumab_D-271.pdf2026-08-26T07:56:56.045Z"300d1611a6c699667f2e553993474afe"216809STANDARD2206203922062039Normalkb-subset/2017-05-22_Wortprotokoll_Vandetanib_D-270.pdf2026-08-26T07:56:56.053Z"199f4b9c716650ef290e46b40cfbf111"252063STANDARD2206203922062039Normalkb-subset/2017-06-01_Wortprotokoll_Pembrolizumab_D-288.pdf2026-08-26T07:56:56.057Z"75c4fd2f962d5892dd39edf5df380df5"134759STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Daratumumab_D-286.pdf2026-08-26T07:56:56.058Z"7fd75d7bfedb92c966690ce4ad003eab"29332STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Daratumumab_D-286_TrG.pdf2026-08-26T07:56:56.063Z"50a0caf715b395497762a586b644167b"57104STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Elbasvir-Grazoprevir_D-268.pdf2026-08-26T07:56:56.067Z"dbdba281b85ce04112014b1081861593"100236STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Elbasvir-Grazoprevir_D-268_TrG.pdf2026-08-26T07:56:56.070Z"c7c0a54b3f9c86a912f286c06f290e48"135505STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Nivolumab_D-267.pdf2026-08-26T07:56:56.073Z"6bd6cfcf0288aa208c01ebb57fff1a2e"66107STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Nivolumab_D-267_TrG.pdf2026-08-26T07:56:56.073Z"0848fb7b238d55511190cfe09eaa3f2b"151733STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Venetoclax_D-266.pdf2026-08-26T07:56:56.109Z"f809976b6f4529510762c807be32a75f"97477STANDARD2206203922062039Normalkb-subset/2017-06-15_AM-RL-XII_Venetoclax_D-266_TrG.pdf2026-08-26T07:56:56.114Z"4a6e3d645124c393fac33b5f566d19eb"140036STANDARD2206203922062039Normalkb-subset/2017-06-20_Wortprotokoll_Pembrolizumab_D-274.pdf2026-08-26T07:56:56.117Z"15e14b15caa3e2e0b98aec28af54b450"354111STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Ixazomib_D-272.pdf2026-08-26T07:56:56.119Z"6abf0207f6563ac7d565471af692600c"424992STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Ixazomib_D-272_EN.pdf2026-08-26T07:56:56.120Z"796eabd26976d643277164b72b8e5728"1458056STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Ixazomib_D-272_TrG.pdf2026-08-26T07:56:56.123Z"74f9cbcefcfd273f53df730393396271"159932STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Ixazomib_D-272_TrG_EN.pdf2026-08-26T07:56:56.129Z"b7940868251c03d25328a8bde7fb272e"781234STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Obeticholsaeure_D-269.pdf2026-08-26T07:56:56.134Z"0a1e73aeb8897966386c4135fe5dc825"162704STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Obeticholsaeure_D-269_TrG.pdf2026-08-26T07:56:56.141Z"03ec220457e4f2d1ce96fd1af146b478"134935STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Reslizumab_D-271.pdf2026-08-26T07:56:56.138Z"120d4c198a072c2c50a830b5d602fd19"151110STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Reslizumab_D-271_TrG.pdf2026-08-26T07:56:56.139Z"3ad8afa4b27df04a2a002f637ebe25ba"274441STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Vandetanib_D-270.pdf2026-08-26T07:56:56.144Z"e25dae1cf2301f366a804ee7866bb6b2"107282STANDARD2206203922062039Normalkb-subset/2017-07-06_AM-RL-XII_Vandetanib_D-270_TrG.pdf2026-08-26T07:56:56.169Z"201d155803f76555efe25733aacf8614"176838STANDARD2206203922062039Normalkb-subset/2017-07-11_Wortprotokoll_Secukinumab_D-276.pdf2026-08-26T07:56:56.180Z"3bc1b4bbf5bc659931a5db4769e50a2c"132204STANDARD2206203922062039Normalkb-subset/2017-07-20_AM-RL-XII_Lonoctocog-alfa_D-273-TrG.pdf2026-08-26T07:56:56.191Z"a8ae65b435e9885655198568e276c8eb"166623STANDARD2206203922062039Normalkb-subset/2017-07-20_AM-RL-XII_Lonoctocog-alfa_D-273.pdf2026-08-26T07:56:56.189Z"2cfb6a6a80d8fdce3ad4bdd400600bef"74998STANDARD2206203922062039Normalkb-subset/2017-08-03_AM-RL-XII_Pembrolizumab_D274.pdf2026-08-26T07:56:56.193Z"67c1ff2bc995f4dcf48761fadd7861f1"138707STANDARD2206203922062039Normalkb-subset/2017-08-03_AM-RL-XII_Pembrolizumab_D274_TrG.pdf2026-08-26T07:56:56.191Z"02869e4b0e131e7a0af6f81e6f50ef0c"265515STANDARD2206203922062039Normalkb-subset/2017-08-07_Wortprotokoll_Axitinib_D-278.pdf2026-08-26T07:56:56.194Z"a6c870776011bce8883aef9578124911"94635STANDARD2206203922062039Normalkb-subset/2017-08-07_Wortprotokoll_Baricitinib_D-279.pdf2026-08-26T07:56:56.200Z"fd172e641f4f01b8097538329bea3c1e"133970STANDARD2206203922062039Normalkb-subset/2017-08-07_Wortprotokoll_Dolutegravir_D-277.pdf2026-08-26T07:56:56.203Z"8a0b3d259c58b7a41fed0289e248e61f"95338STANDARD2206203922062039Normalkb-subset/2017-08-07_Wortprotokoll_Tenofoviralafenamid_D-280.pdf2026-08-26T07:56:56.207Z"5d25cb199165d8918445ff126985f4b9"87504STANDARD2206203922062039Normalkb-subset/2017-08-17_AM-RL-XII_Ixekizumab_D-275.pdf2026-08-26T07:56:56.205Z"45a22bffca3c9913aecdc27e0500297c"163488STANDARD2206203922062039Normalkb-subset/2017-08-17_AM-RL-XII_Ixekizumab_D-275_TrG.pdf2026-08-26T07:56:56.220Z"5d7a652fe21870cd273db68d8288b36d"242223STANDARD2206203922062039Normalkb-subset/2017-08-17_AM-RL-XII_Secukinumab_D-276.pdf2026-08-26T07:56:56.226Z"b1a305845a8abc94a5cda2c7a64879e0"152004STANDARD2206203922062039Normalkb-subset/2017-08-17_AM-RL-XII_Secukinumab_D-276_TrG.pdf2026-08-26T07:56:56.239Z"e2e3de0ba3cf35ad728f5d3770d48372"178323STANDARD2206203922062039Normalkb-subset/2017-09-12_Wortprotokoll_Osimertinib_D-282.pdf2026-08-26T07:56:56.257Z"aff2febd70c59ab80f54b70b9972984c"104395STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Axitinib_D-278.pdf2026-08-26T07:56:56.257Z"f4faf4732370fc08dcb1a69e9a120197"145364STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Axitinib_D-278_TrG.pdf2026-08-26T07:56:56.257Z"b13b1eff5bf4e7fa6065914491a19fd3"186209STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Baricitinib_D-279.pdf2026-08-26T07:56:56.261Z"8bb39bdd573f96b9c340717151fa19a9"183660STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Baricitinib_D-279_TrG.pdf2026-08-26T07:56:56.259Z"c736c63d3fca559828bb03bb27d52517"340428STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Dolutegravir_D-277.pdf2026-08-26T07:56:56.269Z"7703577d8e2536c3fccf149d7dea76fb"116084STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Dolutegravir_D-277_TrG.pdf2026-08-26T07:56:56.269Z"a107a61919318f59f05d71784dfe36bb"221876STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Tenofoviralafenamid_D-280.pdf2026-08-26T07:56:56.270Z"70a56db14b1f2d065b0a156f8b34e87b"60464STANDARD2206203922062039Normalkb-subset/2017-09-21_AM-RL-XII_Tenofoviralafenamid_D-280_TrG.pdf2026-08-26T07:56:56.276Z"f655adf0230856d729bfa65c3738df49"182279STANDARD2206203922062039Normalkb-subset/2017-10-15_Wortprotokoll_Telotristatethyl-D-318.pdf2026-08-26T07:56:56.281Z"38bb0cc40eb06b842804faeda16993f2"134844STANDARD2206203922062039Normalkb-subset/2017-10-19_35a_Freistellung_Dinutuximab-beta_F-004.pdf2026-08-26T07:56:56.281Z"bc4d703d65e4e21765bf74d4f7843786"28228STANDARD2206203922062039Normalkb-subset/2017-10-19_35a_Freistellung_Dinutuximab-beta_F-004_TrG.pdf2026-08-26T07:56:56.312Z"060df5a7744ad7033e2cd5c85b7116b5"54321STANDARD2206203922062039Normalkb-subset/2017-10-19_35a_Freistellung_Landiololhydrochlorid_F-001w.pdf2026-08-26T07:56:56.318Z"6c4cb572ba143c0e8a6aab5e125efcb7"28531STANDARD2206203922062039Normalkb-subset/2017-10-19_35a_Freistellung_Landiololhydrochlorid_F-001w_TrG.pdf2026-08-26T07:56:56.322Z"8f31cb94632cba618975fa4062c08c00"54785STANDARD2206203922062039Normalkb-subset/2017-10-19_35a_Freistellung_Lutetium-177Lu-Oxodotreotid_F-003.pdf2026-08-26T07:56:56.331Z"83fb0fdbf26951b68aab2e2d4d3c59fc"28214STANDARD2206203922062039Normalkb-subset/2017-10-19_35a_Freistellung_Lutetium-177Lu-Oxodotreotid_F-003_TrG.pdf2026-08-26T07:56:56.326Z"88e8a7e6a55f16f31e52ec22648e52bf"54232STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Alectinib_D-281.pdf2026-08-26T07:56:56.328Z"cc17a311304f7b7abfd8520db4456981"147029STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Alectinib_D-281_TrG.pdf2026-08-26T07:56:56.328Z"a6804ea6ffd927e16691ee25ff598898"187187STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Ceritinib_D-259_BAnz.pdf2026-08-26T07:56:56.332Z"5badda589cbdee748a09b5617bd8fa08"640936STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Dabrafenib_D-285.pdf2026-08-26T07:56:56.337Z"4364b050204b4b878360345a67487021"81868STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Dabrafenib_D-285_TrG.pdf2026-08-26T07:56:56.339Z"96a5591503ca30ee05458a3b0df27487"219915STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Osimertinib_D-282.pdf2026-08-26T07:56:56.352Z"0df47bdbbfac43690567d01f928c7f96"177081STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Osimertinib_D-282_TrG.pdf2026-08-26T07:56:56.351Z"245c56603e3ca1a6d88fbb7458f1ca23"236868STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Tofacitinib_D-283.pdf2026-08-26T07:56:56.384Z"7bb3f14db3a36ee02fc34472d9b0d9fd"250898STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Tofacitinib_D-283_TrG.pdf2026-08-26T07:56:56.384Z"62fd9c204b204232a33c39e5c04da63f"392475STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Trametinib_D-284.pdf2026-08-26T07:56:56.384Z"3d6db563018c7d7f48b63ed0d5f6c2fe"82301STANDARD2206203922062039Normalkb-subset/2017-10-19_AM-RL-XII_Trametinib_D-284_TrG.pdf2026-08-26T07:56:56.387Z"d59d825b4541add8c4f92bd3d1d7df50"220403STANDARD2206203922062039Normalkb-subset/2017-11-02_Wortprotokoll_Blinatumomab_D-289.docx.pdf2026-08-26T07:56:56.387Z"05a82cfe966da50bc7f759cd508d1fc3"158893STANDARD2206203922062039Normalkb-subset/2017-11-06_Wortprotokoll_Cerliponase_alfa_D-298.pdf2026-08-26T07:56:56.388Z"6defa8750523200e1c394910768cc09b"168055STANDARD2206203922062039Normalkb-subset/2017-11-06_Wortprotokoll_Nivolumab_D-293.pdf2026-08-26T07:56:56.394Z"a423e74bde8719f1aef6166430bdce62"140786STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Etelcalcetid_D-287.pdf2026-08-26T07:56:56.394Z"2a7f8d27aeef94d33d59e5026c0c0b88"75447STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Etelcalcetid_D-287_TrG.pdf2026-08-26T07:56:56.401Z"f80d3b2633b2213ee066b136ff41a913"141001STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Nivolumab_D-291.pdf2026-08-26T07:56:56.414Z"cf6a68afbc4000420309a62f6057b183"150479STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Nivolumab_D-291_TrG.pdf2026-08-26T07:56:56.414Z"8925af4727218be22162c7af32041ef3"247687STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Pembrolizumab_D-288.pdf2026-08-26T07:56:56.426Z"5f9fbb4532c688daff543f13e91ae008"49951STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Pembrolizumab_D-288_TrG.pdf2026-08-26T07:56:56.445Z"76c44606f4a19604788057b05155afda"107118STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Rolapitant_D-290.pdf2026-08-26T07:56:56.449Z"4d442b4bccbec88dea9065ba5a8589c7"102642STANDARD2206203922062039Normalkb-subset/2017-11-17_AM-RL-XII_Rolapitant_D-290_TrG.pdf2026-08-26T07:56:56.457Z"e3faa378ad0e7d1ac960313ef5a0ade1"250857STANDARD2206203922062039Normalkb-subset/2017-11-28_Wortprotokoll_Inotuzumab-OzogamicinD-297.pdf2026-08-26T07:56:56.455Z"e75ef9886feec6fd9958223f7bd95bc2"211569STANDARD2206203922062039Normalkb-subset/2017-12-01_Wortprotokoll_Guselkumab_D-330.pdf2026-08-26T07:56:56.456Z"bc0b14eae82b5b6ffdbe40f87ccde868"117088STANDARD2206203922062039Normalkb-subset/2017-12-01_Wortprotokoll_Perampanel_D-325.pdf2026-08-26T07:56:56.459Z"81ff545de0a46a87f26c170f6ebe5f21"136751STANDARD2206203922062039Normalkb-subset/2017-12-07_AM-RL-XII_Blinatumomab_D-289.pdf2026-08-26T07:56:56.460Z"fc44102db4d08f3c1f041b9b37e18f3c"125977STANDARD2206203922062039Normalkb-subset/2017-12-07_AM-RL-XII_Blinatumomab_D-289_TrG.pdf2026-08-26T07:56:56.471Z"e1bd6048b848921c05153ea8bd4e100f"165013STANDARD2206203922062039Normalkb-subset/2017-12-07_AM-RL-XII_Nivolumab-Ipilimumab_D-295.pdf2026-08-26T07:56:56.473Z"6af025d790ef923d71f2cefca41fbb81"53042STANDARD2206203922062039Normalkb-subset/2017-12-07_AM-RL-XII_Nivolumab-Ipilimumab_D-295_TrG.pdf2026-08-26T07:56:56.486Z"c527d2b9c06a936a9e1c56d08e0b2e26"236726STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Cerliponase-alfa_D-298.pdf2026-08-26T07:56:56.484Z"932f76bb8038c19fea30777265108980"123060STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Cerliponase-alfa_D-298_EN.pdf2026-08-26T07:56:56.498Z"ac760e44e2565f6646041af9e1f4348e"1313521STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Cerliponase-alfa_D-298_TrG.pdf2026-08-26T07:56:56.508Z"538dffede0892727213b14ff62a3fa4f"150090STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Cerliponase-alfa_D-298_TrG_EN.pdf2026-08-26T07:56:56.518Z"1c383ee4a49cf2f9e706f0d391287308"769823STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Nivolumab_D-293.pdf2026-08-26T07:56:56.527Z"0ccb124b1d5571fe615ba6612b5db005"76498STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Nivolumab_D-293_TrG.pdf2026-08-26T07:56:56.531Z"3c8bc6e5d3646f64d50b4b8f3ab39864"145681STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Nusinersen_D-294.pdf2026-08-26T07:56:56.532Z"49c00fe4716802335124bee414100ed5"95831STANDARD2206203922062039Normalkb-subset/2017-12-21_AM-RL-XII_Nusinersen_D-294_TrG.pdf2026-08-26T07:56:56.532Z"7f74ab992ce49abd68a98510482ccbce"149963STANDARD2206203922062039Normalkb-subset/2017_02_06_Lenvatinib_Wortprotokoll_D-257.pdf2026-08-26T07:56:56.535Z"ab750ce2a7821ece8dea2bb713ad71dd"126972STANDARD2206203922062039Normalkb-subset/2017_02_06_Wortprotokoll_Crizotinib_D-261.pdf2026-08-26T07:56:56.545Z"91821509b8d238dc9e35c86851fc1ef3"115216STANDARD2206203922062039Normalkb-subset/2017_02_06_Wortprotokoll_Ibrutinib_D-262.pdf2026-08-26T07:56:56.543Z"eaa5f72ee131b28a89e160d3cf3b6651"101064STANDARD2206203922062039Normalkb-subset/2017_02_06_Wortprotokoll_Idelalisib_D-256.pdf2026-08-26T07:56:56.546Z"32dd7f57db77f8e55001a07a15869be5"99440STANDARD2206203922062039Normalkb-subset/2017_02_06_Wortprotokoll_Opicapon_D-258.pdf2026-08-26T07:56:56.564Z"b52736e7467e582086acd96c4f08dbbb"160827STANDARD2206203922062039Normalkb-subset/2017_04_11_Wortprotokoll_Olaratumab-D-265.pdf2026-08-26T07:56:56.566Z"0f4a76fc8641b7da8ea3e6ee2ccc2ce3"106680STANDARD2206203922062039Normalkb-subset/2017_04_11_Wortprotokoll_Palbociclib_D-264.pdf2026-08-26T07:56:56.577Z"930d8017b5f8454c1b221aba615c3568"264277STANDARD2206203922062039Normalkb-subset/2017_04_25_Wortprotokoll_Elbasvir-Grazoprevir_D-268.pdf2026-08-26T07:56:56.591Z"8474ebff85be5b62a5370f9dd3b97871"136186STANDARD2206203922062039Normalkb-subset/2017_06_06_Wortprotokoll_Lonoctocog-D-273.pdf2026-08-26T07:56:56.590Z"78cd9c477d0ca5cd03280de0a3790976"115667STANDARD2206203922062039Normalkb-subset/2017_07_11_Wortprotokoll_Ixekizumab_D-275.pdf2026-08-26T07:56:56.597Z"e8b61c33a15a30f124f1d4b1219f9cc6"162494STANDARD2206203922062039Normalkb-subset/2017_09_12_Wortprotokoll_Alectinib_D-281.pdf2026-08-26T07:56:56.606Z"b9b200e17cccc835072bbcd6f392882a"106624STANDARD2206203922062039Normalkb-subset/2017_09_12_Wortprotokoll_Dabrafenib_D-285.pdf2026-08-26T07:56:56.602Z"865b14223ce18929b241e0fdc65b5c16"146684STANDARD2206203922062039Normalkb-subset/2017_09_12_Wortprotokoll_Tofacitinib_D-283.pdf2026-08-26T07:56:56.605Z"caa0575ec988e9f954e3ee3c053fb966"155704STANDARD2206203922062039Normalkb-subset/2017_09_12_Wortprotokoll_Trametinib_D-284.pdf2026-08-26T07:56:56.615Z"59b9488ddd7d3cdad825d0d6785a1bcf"146691STANDARD2206203922062039Normalkb-subset/2017_10_09_Rolapitant_Wortprotokoll_D-290.pdf2026-08-26T07:56:56.607Z"1d5ffd8cc88e59e63ba3366996da0dc3"74437STANDARD2206203922062039Normalkb-subset/2017_10_09_Wortprotokoll_Etelcalcetid_D-287.pdf2026-08-26T07:56:56.617Z"245f878e2720885507e0d9185b1471eb"124176STANDARD2206203922062039Normalkb-subset/2017_10_09_Wortprotokoll_Nivolumab_D-291.pdf2026-08-26T07:56:56.634Z"3b77318faaa4502d5841712132959b18"142272STANDARD2206203922062039Normalkb-subset/2017_10_15_Wortprotokoll_Obinutuzumab_nAWG_D-305.pdf2026-08-26T07:56:56.637Z"abc99e344759e053e428a7480a2c37cc"158528STANDARD2206203922062039Normalkb-subset/2017_10_24_Wortprotokoll_Nivolumab_D-295.pdf2026-08-26T07:56:56.653Z"894c068de448a172233d05d3254e0e38"109527STANDARD2206203922062039Normalkb-subset/2017_11_06_Wortprotokoll_Nusinersen_D-294.pdf2026-08-26T07:56:56.659Z"10e132c38941bc38fa6e6a8d2f9f649b"126074STANDARD2206203922062039Normalkb-subset/2017_12_01_Wortprotokoll_Dupilumab_D-328.pdf2026-08-26T07:56:56.660Z"0ae2072ff62d3567e23ee8a451445296"126487STANDARD2206203922062039Normalkb-subset/2017_12_11_Wortprotokoll_Ceritinib_D-296.pdf2026-08-26T07:56:56.673Z"816354372ca073e83423cda3dcdbed09"143422STANDARD2206203922062039Normalkb-subset/2017_12_11_Wortprotokoll_Glecaprevir_Pibrentasvir_D-301.pdf2026-08-26T07:56:56.680Z"c0e1206a4640e2f97583b55230fa2ccc"131312STANDARD2206203922062039Normalkb-subset/2017_12_11_Wortprotokoll_Saxagliptin_Metformin_nAWG_D-306.pdf2026-08-26T07:56:56.682Z"e6c007ef626e79e7b89c3dc4b297ed8b"47376STANDARD2206203922062039Normalkb-subset/2018-01-17_Wortprotokoll_Ledipasvir-Sofosbuvir-nAWG_D-304.pdf2026-08-26T07:56:56.680Z"37b2064225b372e3d336fd6aa669bf1c"48638STANDARD2206203922062039Normalkb-subset/2018-01-18_AM-RL-XII_Inotuzumab-Ozogamicin_D-297.pdf2026-08-26T07:56:56.678Z"7134c09aee02e7e49e4ff11b4184ef3b"120106STANDARD2206203922062039Normalkb-subset/2018-01-18_AM-RL-XII_Inotuzumab-Ozogamicin_D-297_TrG_1_.pdf2026-08-26T07:56:56.692Z"be008842257529ecbcff759ea131a406"186879STANDARD2206203922062039Normalkb-subset/2018-01-22_Wortprotokoll_Ribociclib_D-307.pdf2026-08-26T07:56:56.686Z"cc06164f0840285b2b15229c43f7aaee"200265STANDARD2206203922062039Normalkb-subset/2018-02-01_AM-RL-XII_Ceritinib_nAWG_D-296.pdf2026-08-26T07:56:56.712Z"e39cb4071efcb71e91134d446b8e6dc0"41419STANDARD2206203922062039Normalkb-subset/2018-02-01_AM-RL-XII_Ceritinib_nAWG_D-296_TrG.pdf2026-08-26T07:56:56.718Z"ea79dd64b2a244cfba6160c61e2a4fda"101502STANDARD2206203922062039Normalkb-subset/2018-02-01_AM-RL-XII_Glecaprevir-Pibrentasvir_D-301.pdf2026-08-26T07:56:56.720Z"b6d892b2fc529fe23ba2db4e4f4b38f0"80365STANDARD2206203922062039Normalkb-subset/2018-02-01_AM-RL-XII_Glecaprevir-Pibrentasvir_D-301_TrG.pdf2026-08-26T07:56:56.728Z"64ea598b42c9701ffaa0feae025cb13a"228795STANDARD2206203922062039Normalkb-subset/2018-02-01_AM-RL-XII_Saxagliptin_Metformin_D-306.pdf2026-08-26T07:56:56.729Z"ce63c57187adc5aca040202e51d2557d"179037STANDARD2206203922062039Normalkb-subset/2018-02-01_AM-RL-XII_Saxagliptin_Metformin_D-306_TrG.pdf2026-08-26T07:56:56.734Z"6d3cdb1004ad37c3173a8b977586bcb6"251926STANDARD2206203922062039Normalkb-subset/2018-02-05_Wortprotokoll_Atezolizumab-Urothelkarzinom_D-314.pdf2026-08-26T07:56:56.756Z"b2d0f1122c7a4bcb21558d8549d5a719"109281STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Carfilzomib_D-302.pdf2026-08-26T07:56:56.751Z"66a87b7946fbeab8a5e5b69ab3ecb473"208960STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Carfilzomib_D-302_TrG.pdf2026-08-26T07:56:56.760Z"e1ed56e8d8a6c3ecce888cc556dfaa8d"259259STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Ledipasvir-Sofosbuvir-nAWG_D-304.pdf2026-08-26T07:56:56.757Z"0b4eaa4a5c58de03e2fef401d54b9ed5"73106STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Ledipasvir-Sofosbuvir-nAWG_D-304_TrG.pdf2026-08-26T07:56:56.763Z"67df5b63e7775d1c55319ff20fe1df4f"180501STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Sarilumab_D-299.pdf2026-08-26T07:56:56.767Z"a049b66c721cd67fd21e896cd7be244f"179731STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Sarilumab_D-299_TrG.pdf2026-08-26T07:56:56.784Z"2e918cc256237835f625f67ab8f1e1e0"304127STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Sofosbuvir-Velpatasvir-Voxilaprevir_D-300.pdf2026-08-26T07:56:56.783Z"0521dfd6c81a765e01b1bc3ae48dc900"160312STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL-XII_Sofosbuvir-Velpatasvir-Voxilaprevir_D-300_TrG.pdf2026-08-26T07:56:56.793Z"d335f207b20554dd469d0fa48840f2c8"147560STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL_XII_Daratumumab_D-310.pdf2026-08-26T07:56:56.800Z"18323da6f159813254a36c7d7247cd45"195249STANDARD2206203922062039Normalkb-subset/2018-02-15_AM-RL_XII_Daratumumab_D-310_TrG.pdf2026-08-26T07:56:56.800Z"e2c42a97c312a41b0e886c09838881a2"270669STANDARD2206203922062039Normalkb-subset/2018-02-19_Wortprotokoll_Cabozantinib_D-317.pdf2026-08-26T07:56:56.803Z"901936728269a88be045a1e23b983820"115411STANDARD2206203922062039Normalkb-subset/2018-03-01_AM-RL-XII_Brodalumab_D-309.pdf2026-08-26T07:56:56.820Z"5d84e4164cb31268e16d324446debe84"100068STANDARD2206203922062039Normalkb-subset/2018-03-01_AM-RL-XII_Brodalumab_D-309_TrG.pdf2026-08-26T07:56:56.821Z"98e898bfde9c03107e38b65b75b5d5bd"176065STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Atezolizumab_D-313.pdf2026-08-26T07:56:56.825Z"84248a0e37eb6d15bcf7f1e56615d7c9"142342STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Atezolizumab_D-313_TrG.pdf2026-08-26T07:56:56.828Z"e7ee6e9ab062197a6d4442c4d896dd4d"180858STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Atezolizumab_D-314.pdf2026-08-26T07:56:56.832Z"352073392021302e03d3d6470b8c4299"111928STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Atezolizumab_D-314_TrG.pdf2026-08-26T07:56:56.837Z"27d2282a3c6391ffa9a50f92a0c90a9d"172553STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Avelumab_D-308.pdf2026-08-26T07:56:56.860Z"67423269ea21da0dc2541fa0f8fb1c48"94509STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Avelumab_D-308_TrG.pdf2026-08-26T07:56:56.861Z"f34a457f8c919ec3c46bb5100c6e9299"134759STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Darunavir-Kombi_D-321.pdf2026-08-26T07:56:56.864Z"e5a6fbdceebedcc057886a21566e85f4"70235STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Darunavir-Kombi_D-321_TrG.pdf2026-08-26T07:56:56.865Z"7728238cffd36bf08200be8d076f4e34"153680STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Dimethylfumarat_D-316.pdf2026-08-26T07:56:56.867Z"50633a405ce65bc0bf7fa6f2d1205393"54909STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Dimethylfumarat_D-316_TrG.pdf2026-08-26T07:56:56.871Z"b7b94abea56a85da290194bfbfe9a3a5"132139STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Elosulfase_20alfa_D-320.pdf2026-08-26T07:56:56.895Z"b7dc854c41923e5be3bf4374c2bea956"124187STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Elosulfase_20alfa_D-320_TrG.pdf2026-08-26T07:56:56.895Z"b43ff35870fbc9aab39c059765cdc9e6"143243STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Pembrolizumab_D-311.pdf2026-08-26T07:56:56.897Z"292ee5c7e218082180a373aee98c5d51"118740STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Pembrolizumab_D-311_TrG.pdf2026-08-26T07:56:56.898Z"9d1a57229ab61bf94cc8de3d32f4eae8"168981STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Ribociclib_D-307.pdf2026-08-26T07:56:56.901Z"526f7be997427b065cf8745d7fdd46dd"119186STANDARD2206203922062039Normalkb-subset/2018-03-16_AM-RL-XII_Ribociclib_D-307_TrG.pdf2026-08-26T07:56:56.902Z"3ca85bdae9c1f8e2bf2f154846533ca1"158199STANDARD2206203922062039Normalkb-subset/2018-03-20_AM-RL-XII_Glecaprevir-Pibrentasvir_D-301_BAnz.pdf2026-08-26T07:56:56.934Z"2c39af9c7eb4b48dc122bdab9f0b8a93"664065STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Cabozantinib_D-317.pdf2026-08-26T07:56:56.935Z"997897c74021b8718744406df9aa6025"115948STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Cabozantinib_D-317_TrG.pdf2026-08-26T07:56:56.939Z"925e78602b3cb21a7957e31ca6734fd3"165956STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Midostaurin_AML_D-319.pdf2026-08-26T07:56:56.939Z"945bb61020a2de6145c6c9427e9f449c"117637STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Midostaurin_AML_D-319_TrG.pdf2026-08-26T07:56:56.944Z"b7f986b5c857377090f53b4255e47c5a"139656STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Midostaurin_ASM_D-319.pdf2026-08-26T07:56:56.946Z"03d1e933d2e2d4983e075cde7b7b6f04"92327STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Midostaurin_ASM_D-319_TrG.pdf2026-08-26T07:56:56.959Z"5ee08b6669ccd9283f37db7a7ab6f885"118080STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Obinutuzumab_nAWG_D-305.pdf2026-08-26T07:56:56.962Z"786f6c132e5cff2177e70dc47fc7f58e"118768STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Obinutuzumab_nAWG_D-305_TrG.pdf2026-08-26T07:56:56.961Z"bdfeb5de5ff51c07eb1f60170b025d7d"163046STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Sofosbuvir-nAWG_D-312.pdf2026-08-26T07:56:56.972Z"82bb2a7b580f1ad61f86c20b3e361f46"68689STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Sofosbuvir-nAWG_D-312_TrG.pdf2026-08-26T07:56:56.974Z"77c6b1d62e18dc0cd6050c1c93658463"140771STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Telotristatethyl_D-318.pdf2026-08-26T07:56:56.980Z"33b9057b39879b5959290d1a678b7e03"143365STANDARD2206203922062039Normalkb-subset/2018-04-05_AM-RL-XII_Telotristatethyl_D-318_TrG.pdf2026-08-26T07:56:56.995Z"232fe5c5149ffbf87cd2257eaeb1c3db"148160STANDARD2206203922062039Normalkb-subset/2018-04-19_AM-RL-XII_Nonacog-beta-pegol_D-322.pdf2026-08-26T07:56:57.004Z"0bb060924f8882922e46d1aa21941308"57064STANDARD2206203922062039Normalkb-subset/2018-04-19_AM-RL-XII_Nonacog-beta-pegol_D-322_TrG.pdf2026-08-26T07:56:57.008Z"6fe171681c37dba7affbc59ca9d0139f"115671STANDARD2206203922062039Normalkb-subset/2018-04-19_AM-RL-XII_Tivozanib_D-323.pdf2026-08-26T07:56:57.007Z"e295534b705612a0a273956a79117ee2"122316STANDARD2206203922062039Normalkb-subset/2018-04-19_AM-RL-XII_Tivozanib_D-323_TrG.pdf2026-08-26T07:56:57.018Z"30c50f78559125519e769af561e322fa"179164STANDARD2206203922062039Normalkb-subset/2018-04-24_Wortprotokoll_Abirateronacetat-D-337.pdf2026-08-26T07:56:57.021Z"c2c3dd3f0ff5158594288c070ae16616"159696STANDARD2206203922062039Normalkb-subset/2018-04-24_Wortprotokoll_Niraparib_D-331.pdf2026-08-26T07:56:57.024Z"2b03f8110835214a90ba58395f5e4413"140093STANDARD2206203922062039Normalkb-subset/2018-05-03_AM-RL-XII_Cenegermin-D-329.pdf2026-08-26T07:56:57.025Z"1287d918f8252924e075bd4e37bbd16c"114806STANDARD2206203922062039Normalkb-subset/2018-05-03_AM-RL-XII_Cenegermin-D-329_TrG.pdf2026-08-26T07:56:57.033Z"6e3594e874b4851397e2a0119aec30b6"144808STANDARD2206203922062039Normalkb-subset/2018-05-03_AM-RL-XII_Elvitegravir-Kombi-D-324.pdf2026-08-26T07:56:57.039Z"60a72fa4618c256e49468211c96091b5"67289STANDARD2206203922062039Normalkb-subset/2018-05-03_AM-RL-XII_Elvitegravir-Kombi-D-324_TrG.pdf2026-08-26T07:56:57.049Z"089e924f76220d11c7d8bfa3acdacb70"122307STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Cladibrin_D-327.pdf2026-08-26T07:56:57.053Z"c18ee359ee864e50b2320fb8c717738d"57669STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Cladibrin_D-327_TrG.pdf2026-08-26T07:56:57.070Z"2d65e0daaa834815cc10d74c9f175223"197792STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Dupilumab_D-328.pdf2026-08-26T07:56:57.070Z"e185cd473d9a3fefa15e34dad06508c0"131434STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Dupilumab_D-328_TrG.pdf2026-08-26T07:56:57.076Z"8fb04ec2a7248885a8c8540321a3ad4b"178131STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Guselkumab_D-330.pdf2026-08-26T07:56:57.081Z"520a29f28174cd3f5374dbbcca92f46f"278543STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Guselkumab_D-330_TrG.pdf2026-08-26T07:56:57.081Z"3a18c8ffb8add1b4689b621ede74a88c"229994STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Perampanel_D-325.pdf2026-08-26T07:56:57.089Z"e00df98834ce8523d328fd72726addb0"40530STANDARD2206203922062039Normalkb-subset/2018-05-17_AM-RL-XII_Perampanel_D-325_TrG.pdf2026-08-26T07:56:57.091Z"42e3f187cc0374274ee9ec439306118a"99754STANDARD2206203922062039Normalkb-subset/2018-05-22_AM-RL-XII_Tivozanib-Therapiekosten_D323_BAnz.pdf2026-08-26T07:56:57.097Z"b9ad97fef3cd1b0381a1d1c056f83ae6"644311STANDARD2206203922062039Normalkb-subset/2018-05-22_Wortprotokoll_Allogene-T-Zellen_D-333.pdf2026-08-26T07:56:57.101Z"368d2fb89fb0542e732235d012339920"149486STANDARD2206203922062039Normalkb-subset/2018-06-01_Wortprotokoll_Bosutinib_D-355.pdf2026-08-26T07:56:57.102Z"b3321301da11f46c390aa1c53432326b"164362STANDARD2206203922062039Normalkb-subset/2018-06-07_AM-RL-XII_Abirateronacetat-nAWG_D-337.pdf2026-08-26T07:56:57.112Z"72b5a42a9878a27d3b5d23a4b9e501bb"166963STANDARD2206203922062039Normalkb-subset/2018-06-07_AM-RL-XII_Abirateronacetat-nAWG_D-337_TrG.pdf2026-08-26T07:56:57.118Z"d7a3c4a0b7dd7246200518b555d803b7"177262STANDARD2206203922062039Normalkb-subset/2018-06-07_AM-RL-XII_Darunavir-Kombi-Therapiekosten_D-321_BAnz.pdf2026-08-26T07:56:57.144Z"0e636e5fa8066d26d653a6196305167d"573946STANDARD2206203922062039Normalkb-subset/2018-06-07_AM-RL-XII_Niraparib_D-331.pdf2026-08-26T07:56:57.144Z"435cb75b9fc39c875def592b83ccc98a"148177STANDARD2206203922062039Normalkb-subset/2018-06-07_AM-RL-XII_Niraparib_D-331_TrG.pdf2026-08-26T07:56:57.143Z"1be77f2006d6e5fb00e70b4356396577"114169STANDARD2206203922062039Normalkb-subset/2018-06-12_Wortprotokoll_Ocrelizumab_D-332.pdf2026-08-26T07:56:57.148Z"7ffb1f28ab256851e823ad5c2d341ff9"162724STANDARD2206203922062039Normalkb-subset/2018-06-15_Wortprotokoll_Cabozantinib_nAWG_D-367.pdf2026-08-26T07:56:57.148Z"ed7a1908d913d5ed8d52f0d0636103f2"93203STANDARD2206203922062039Normalkb-subset/2018-06-15_Wortprotokoll_Dolutegravir_Rilpivirin_D-362.pdf2026-08-26T07:56:57.154Z"6a55b7c5d62864380c0b0b7307d337ea"144080STANDARD2206203922062039Normalkb-subset/2018-06-15_Wortprotokoll_Nivolumab-D-370.pdf2026-08-26T07:56:57.159Z"ed21c08cc1cb3f380d1045553cccfb18"210676STANDARD2206203922062039Normalkb-subset/2018-06-15_Wortprotokoll_Olaparib_nAWG_D-360.pdf2026-08-26T07:56:57.158Z"30e3947218c99d9c045b5edc81d89597"133883STANDARD2206203922062039Normalkb-subset/2018-06-21_AM-RL-XII_Alectinib_D-326.pdf2026-08-26T07:56:57.177Z"6cc147557286b5c73c7f0f34c591df5e"120539STANDARD2206203922062039Normalkb-subset/2018-06-21_AM-RL-XII_Alectinib_D-326_TrG.pdf2026-08-26T07:56:57.170Z"9447935773e1501131cbfad77efc5e3e"160882STANDARD2206203922062039Normalkb-subset/2018-06-21_AM-RL-XII_Cladribin-Therapiekosten_D-327_BAnz.pdf2026-08-26T07:56:57.177Z"be5ebd351b56f21b5737b9aa6345e172"659983STANDARD2206203922062039Normalkb-subset/2018-06-21_AM-RL-XII_Dapagliflozin_D-335.pdf2026-08-26T07:56:57.181Z"af2e3fc247e7fc57ea1dc54db6e463ef"137634STANDARD2206203922062039Normalkb-subset/2018-06-21_AM-RL-XII_Dapagliflozin_D-335_TrG.pdf2026-08-26T07:56:57.221Z"c610cab7bb2ba357807c093cd2329cfa"179786STANDARD2206203922062039Normalkb-subset/2018-06-21_AM-RL-XII_Dapagliflozin_Metformin_D-336.pdf2026-08-26T07:56:57.222Z"39a14682fe941b342daa5bb0bf6fb7e5"131512STANDARD2206203922062039Normalkb-subset/2018-06-21_AM-RL-XII_Dapagliflozin_Metformin_D-336_TrG.pdf2026-08-26T07:56:57.223Z"70b53fb0fa74a73566d990a804cb226f"188397STANDARD2206203922062039Normalkb-subset/2018-06-25_Wortprotokoll_Ipilimumab_D-350.pdf2026-08-26T07:56:57.226Z"3d328c81784a8663ca3fdb08685ede9e"57203STANDARD2206203922062039Normalkb-subset/2018-06-26_AM-RL-XII_Nonacoq_beta_pegol-Aenderung-Therapiekosten_D-322_BAnz.pdf2026-08-26T07:56:57.229Z"678ec48c6247da64b6390b80f0c4c8a0"671032STANDARD2206203922062039Normalkb-subset/2018-07-01_Wortprotokoll_BET_D-364.pdf2026-08-26T07:56:57.231Z"457e18ff897378801b12552c67397811"94902STANDARD2206203922062039Normalkb-subset/2018-07-01_Wortprotokoll_Ipilimumab_nAWG_D-372.pdf2026-08-26T07:56:57.232Z"a5cec569ba9ee706566a020646a8414a"210692STANDARD2206203922062039Normalkb-subset/2018-07-01_Wortprotokoll_Velmanase_20alfa_D-365.pdf2026-08-26T07:56:57.238Z"ec6c9607ce6bf3aa226ed99ef98c99b5"72484STANDARD2206203922062039Normalkb-subset/2018-07-05_AM-RL-XII_Brentuximab_Vedotin_D-340.pdf2026-08-26T07:56:57.241Z"ede6cdfd699cfa5a82f49d3798db6873"305983STANDARD2206203922062039Normalkb-subset/2018-07-05_AM-RL-XII_Brentuximab_Vedotin_D-340_TrG.pdf2026-08-26T07:56:57.248Z"3c587e3e197944acd89b93fa3397fa60"383715STANDARD2206203922062039Normalkb-subset/2018-07-05_AM-RL-XII_Elvitegravir-Cobicistat-Emtricitabin-Tenofoviralafenamid_D-334.pdf2026-08-26T07:56:57.248Z"49d487e83ded8d40493c87f6ed3c0285"100501STANDARD2206203922062039Normalkb-subset/2018-07-05_AM-RL-XII_Elvitegravir-Cobicistat-Emtricitabin-Tenofoviralafenamid_D-334_TrG.pdf2026-08-26T07:56:57.247Z"ab5593024f397b161228c387956fb932"171930STANDARD2206203922062039Normalkb-subset/2018-07-05_AM-RL-XII_allogene_genetisch_modifizierte_T-Zellen_D-333.pdf2026-08-26T07:56:57.282Z"9db2b2b30feee21cba5502190adf9f4c"121331STANDARD2206203922062039Normalkb-subset/2018-07-05_AM-RL-XII_allogene_genetisch_modifizierte_T-Zellen_D-333_TrG.pdf2026-08-26T07:56:57.289Z"b36b87582164e25edde6bf61f7a8cfb3"110215STANDARD2206203922062039Normalkb-subset/2018-07-09_Wortprotokoll_Insulin-glargin_Lixisenatid_D-346.pdf2026-08-26T07:56:57.296Z"43ebd72382044a70bb9ecb4495624507"181194STANDARD2206203922062039Normalkb-subset/2018-07-09_Wortprotokoll_Ixekizumab_D-343.pdf2026-08-26T07:56:57.299Z"c4793b98adf42a0a557d7d7b51cfa89b"104102STANDARD2206203922062039Normalkb-subset/2018-07-24_AM-RL-XII_Guselkumab-Therapiekosten_D-330_BAnz.pdf2026-08-26T07:56:57.301Z"b46c745fa5cc6f25f489bc0d2dfab962"670120STANDARD2206203922062039Normalkb-subset/2018-07-24_Wortprotokoll_Evolocumab_D-345.pdf2026-08-26T07:56:57.306Z"0b197e4981e2f004a0ba2731f315e30b"287616STANDARD2206203922062039Normalkb-subset/2018-07-24_Wortprotokoll_Evolocumab_D-345.pdf